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ABSTRACT
Background and aims. Migraine is a common disease in children and 
adolescents, affecting roughly 10% of school-aged children. Recent studies 
have revealed an increasing incidence of childhood migraine, but migraine 
remains an underrecognized and undertreated condition in the pediatric 
population. Migraine attacks are painful and disabling and can affect a child´s 
life in many ways. Effective drug treatment is usually needed. The new 
migraine drugs, triptans, were introduced at the beginning of the 1990s and 
have since been shown to be very effective in the treatment of migraine 
attacks in adults. Although they are widely used in adults, the acute treatment 
of migraine in children and adolescents is still based on paracetamol and 
nonsteroidal anti-inflammatory drugs. Some children can control their attacks 
satisfactorily with these simple analgesics, but at least one-third need more 
powerful treatments. When this thesis work commenced, hardly any 
information existed on the efficacy and safety of triptans in children. The 
study aim was to to identify more efficient treatments of migraine for 
children and adolescents by investigating the efficacy of sumatriptan and 
rizatriptan in them. Sleep has an impact on migraine in many aspects. Despite 
the clinical relevance and common manifestation of sleep in the context of 
migraine in children, very little research data on the true frequency of sleep 
exist. As sleeping is so often related to childhood migraine, it can be a 
confounding factor in clinical drug trials of migraine treatments in children 
and adolescents. How the results of a sleeping child should be analyzed is 
under continual debate. The aim here was to clarify this issue as well as to 
evaluate the frequency of sleeping during migraine attacks and factors 
affecting frequency.
Methods. In Study I, the frequency of children falling asleep during migraine 
attacks was evaluated from 999 migraine attacks registered in headache 
diaries. Data were prospectively collected during a previous study of optimal 
drug treatment of childhood migraine. Study II was a placebo-controlled 
double-blind two-way cross-over trial investigating the efficacy of nasal 
sumatriptan in the treatment of migraine attacks in 94 children aged 8-17 
years. Each child treated two migraine attacks with study drugs, one being 
sumatriptan and the other a placebo. Sumatriptan dose was 10 mg for those 
with a body weight of 20-39 kg and 20 mg for those weighing 40 kg or more. 
Study III was a placebo-controlled double-blind three-way cross-over trial 
examining the efficacy of peroral rizatriptan in treating migraine attacks in 
116 children aged 6-17 years. Each child treated three migraine attacks with 
random order study drugs, one being a placebo and two rizatriptan. The 
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repeated rizatriptan dose tested the stability of the treatment effect in two 
consecutive attacks. Rizatriptan dose was 5 mg for those weighing 20-39 kg 
and 10 mg for those 40 kg or more. In both studies, drug efficacy was 
evaluated with a validated five-face pain intensity scale in a headache diary, 
the primary endpoint being two grade headache relief or sleeping two hours 
postdose.
Results. In Study I, 68% of the children at least occasionally slept during a 
migraine attack. Sleeping was more common in children younger than 8 
years than in older age groups; in the younger age group 57% of attacks were 
relieved by sleep. Pain intensity and duration of migraine attacks increased 
with age, and this was associated with a lower tendency to fall asleep. In 
Study II, nasal sumatriptan was superior to placebo (primary endpoint) 
already one hour postdose and remained superior during the four-hour 
follow-up. At two hours, 64% of patients after sumatriptan and 39% after 
placebo experienced headache relief. All other endpoints also favored 
sumatriptan. In Study III, both doses of rizatriptan were superior to placebo 
one hour postdose and remained superior during the four-hour follow-up. The 
response to rizatriptan was very stable over the two consecutive attacks 
treated. At two hours, 74% of patients after the first and 73% after the second 
dose of rizatriptan experienced headache relief, in contrast to only 36% after 
placebo. Rizatriptan offered complete pain-free response more often than 
placebo, and all other endpoints also favored rizatriptan. No serious adverse 
effects were observed after sumatriptan or rizatriptan.   
Conclusions. Sleeping during migraine attacks is very common, and most 
children at least occasionally sleep during an attack. Falling asleep is 
especially common in children under eight years of age and during the first 
hour after the onset of attack. Children who are able to sleep soon after attack 
onset are more likely pain-free at two hours. Sleeping probably both 
improves recovery from a migraine attack and is a sign of headache relief. 
Falling asleep should be classified as a sign of headache relief in clinical drug 
trials of migraine treatments in children and adolescents. Both sumatriptan 
and rizatriptan are effective and well tolerated in treatment of migraine 
attacks in children and adolescents. The results suggest that nasal sumatriptan 
20 mg and rizatriptan 10 mg can be effectively and safely used to treat 
migraine attacks in adolescents aged over 12 years. Because the treated 
number of patients under 12 years is small, more studies are needed before 
sumatriptan or rizatriptan can be recommended for use in this population. 
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INTRODUCTION
Migraine is the most prevalent neurological disease in children and 
adolescents affecting 4 to 11% of school-aged children, and up to 25% of 
adolescents (Mortimer et al. 1992, Abu-Arafeh et al. 1994, Lewis et al. 
2002). Recent studies have revealed the increasing incidence of childhood 
migraine.  
Migraine attacks are painful and disabling, and can occur several times each 
month. They affect a child´s life in many ways, including school performance 
and relationships with family and peers. However, migraine remains an 
underrecognized, underdiagnosed, and undertreated condition in the pediatric 
population. This is, at least partly, because of different clinical characteristics 
of migraine especially in young children as compared with adults. The 
underlying migraine pathophysiology is, however, presumably the same in 
adults and children. Problems in diagnostics include the short duration of 
childhood migraines, the higher likelihood of a bilateral headache location, 
and a child´s difficulty in describing headache features and associated 
symptoms. Early diagnosis and effective treatment are essential in 
minimizing the impact of migraine on a child’s quality of life and in 
preventing long-term disability (Winner 2008).   
Frequency of migraine attacks in children can often be diminished by 
lifestyle changes and by avoiding attack triggers. Children use 
nonpharmacological treatments to treat their migraine attacks more often than 
adults. However, most children require drug therapy because of the disabling 
migraine symptoms. Pharmacological treatment of migraine in children has 
long been based on nonsteroidal anti-inflammatory drugs (NSAIDs) and 
paracetamol. Some children can control their attacks satisfactorily with these 
simple analgesics, but 30-60% need more effective treatments (Hämäläinen 
et al. 1997). The new migraine drugs, triptans, were introduced at the 
beginning of the 1990s and have since revolutionized migraine treatment in 
adults. However, when this thesis work commenced, there was hardly any 
information on triptan efficacy or safety in children. The purpose of these 
studies was thus to investigate the efficacy of two of these drugs, intranasal 
sumatriptan and oral rizatriptan, in children and adolescents.
Sleeping seems to often be related to resolution of migraine attacks in 
children. Despite the clinical relevance and common manifestation of sleep in 
the context of migraine in children, very little research data on the true 
frequency of sleeping exist. As sleeping occurs so frequently, it can be a 
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confounding factor in clinical drug trials of migraine treatments in children 
and adolescents. How the results of a sleeping child should be analyzed is 
under continual debate, should sleeping be taken as a sign of a positive effect 
of the study drug or should the results of such children be omitted from the 
analyses. The aim here was to clarify this issue as well as to evaluate the 
frequency of sleeping during migraine attacks and factors affecting 
frequency.
Review of the literature
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REVIEW OF THE LITERATURE 
1. Classification and epidemiology of headache in children
Headache, together with abdominal pain and limb pain, is one of the most 
prevalent types of pain, and the most frequent neurological symptom 
experienced by children and adolescents. A large epidemiological study 
reported that 46% of children aged 0-18 years had experienced headache 
during the preceding three months (Perquin et al. 2000). A German study 
described a three-month headache frequency rate of 60.5% in children over 
four years of age (Roth-Isigkeit et al. 2005). A study from Scotland reported 
the prevalence rate of severe recurrent headache to be 20-25% in children 
aged 5-15 years, with only slight variation across the age range (Abu-Arafeh 
et al. 1994). Headaches can be classified according to the International 
Classification of Headache Disorders (Table 1) (Headache Classification 
Committee of the International Headache Society 2004). The most prevalent 
causes of recurrent headache are the primary headaches, in children mainly 
migraine and tension–type headache.  
Table 1. International Classification of Headache Disorders, 2nd edition (Headache 
Classification Committee of the International Headache Society 2004) 
Primary headaches 
                  1. Migraine 
                  2. Tension-type headache (TTH) 
                  3. Cluster headache and other trigeminal autonomic cephalalgias 
                  4. Other primary headaches 
Secondary headaches 
                  5. Headache attributed to head and/or neck trauma 
                  6. Headache attributed to cranial or cervical vascular disorder 
                  7. Headache attributed to nonvascular intracranial disorder 
                  8. Headache attributed to a substance or its withdrawal 
                  9. Headache attributed to infection 
                 10. Headache attributed to disorder of homeostasis  
                 11. Headache of facial pain attributed to disorder of cranium, neck, eyes, ears,     
                        nose, sinuses, teeth, mouth, or other facial or cranial structures 
                 12. Headache attributed to psychiatric disorder   
Cranial neuralgias, central and primary facial pain, and other headaches 
                 13. Cranial neuralgias and central causes of facial pain 
                 14. Other headache, cranial neuralgia, central or primary facial pain 
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Migraine is characterized by episodes of head pain that are often throbbing, 
frequently unilateral, and potentially very severe. In migraine without aura, 
attacks are usually associated with autonomic symptoms such as nausea, 
vomiting, or sensitivity to light, sound, or movement. In roughly one-third of 
migraine patients, attacks are at least sometimes preceded or accompanied by 
transient focal neurological symptoms, the so-called migraine aura (Goadsby 
et al. 2002). Migraine patients have a wide spectrum of phenotypes. Some 
patients have a mild disease with easily controllable attacks, but some have a 
disabling and chronic condition with frequently recurring attacks and difficult 
symptoms. The diagnosis of migraine in both adults and children is based on 
symptoms that fulfill the accepted diagnostic criteria. The diagnostic criteria 
of migraine, introduced in 1988 by the International Headache Society (IHS), 
have enabled accurate diagnostics of migraine (Headache Classification 
Committee of the International Headache Society 1988). The first version of 
the IHS criteria did not include specific criteria for children. The only 
modification made was that the duration of attack was allowed to be shorter 
in children younger than 15 years (2-72 hours) than in adults (4-72 hours). 
These criteria proved, however, to be suitable in diagnostics of migraine also 
in children and adolescents (Hämäläinen et al. 1995), and were quite widely 
adopted for diagnostic purposes. The updated version of IHS criteria 
introduced in 2004 (Headache Classification Committee of the International 
Headache Society 2004) includes specific diagnostic criteria also for children 
(Table 2). The minimum duration of attack was further shortened to one hour, 
and the attack is considered to end at the time of awakening, if a child falls 
asleep.
The prevalence of tension-type headache (TTH) varies in different studies 
according to the criteria applied. The studies that use the International 
Classification of Headache Disorders criteria (Headache Classification 
Committee of the International Headache Society 1988) have reported an 
overall prevalence rate of 10-25% in schoolchildren and adolescents (Anttila 
2006). A prevalence rate as high as 73% was reported in Brazil (Barea et al. 
1996), but in Scandinavian countries the prevalence of TTH has generally 
ranged between 10% and 18% (Anttila et al. 2002, Laurell et al. 2004). 
Consequently, the prevalence of TTH is close to or even higher than the 
prevalence of childhood migraine, which is considered the most common 
cause for recurrent headaches in children (Anttila 2006). 
Children can have headaches for various secondary reasons, such as 
intracranial infections or hemorrhages, brain tumors, arteriovenous 
malformations, disturbances in cerebrospinal fluid flow, systemic diseases, 
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epilepsy, hypertension, sinusitis, ocular or dental diseases, obstructive sleep 
apnea, and psychological reasons (Table 1). Serious causes of secondary 
headache are, however, very rare in children and adolescents. In a Scottish 
follow-up study, three of 815 patients over a seven-year follow-up had 
intracranial pathology explaining the headache (prevalence rate 0.37%) (Abu-
Arafeh et al. 2005).
Table 2. Updated version of the diagnostic criteria for migraine in children and adolescents 
(Headache Classification Committee of the International Headache Society 2004). 
1.1 Migraine without aura 
A. At least five attacks fulfilling criteria B-D 
B. Headache attacks lasting 1-72 hours (untreated or unsuccessfully treated)a
C. Headache has at least two of the following characteristics: 
1. unilateral locationb
2. pulsating quality 
3. moderate or severe pain intensity 
4. aggravation by or causing avoidance of routine physical activity (e.g. 
walking or climbing stairs) 
D. During headache at least one of the following: 
1. nausea and/or vomiting 
2. photophobia and phonophobiac
E. Not attributed to another disorder 
1.2 Migraine with aura 
A. At least two attacks fulfilling criteria B-D 
B. Aura consisting of at least one of the following, but no motor weakness: 
1. fully reversible visual symptoms, including positive features (e.g. flickering 
lights) and/or negative features (i.e. loss of vision) 
2. fully reversible sensory symptoms, including positive features (i.e. pins and 
needles) and/or negative features (i.e. numbness) 
3. fully reversible dysphasic speech disturbance 
C. At least two of the following: 
1. homonymous visual symptoms and/or unilateral sensory symptoms 
2. at least one aura symptom develops gradually over ?5 minutes 
3. each symptom lasts ?5 minutes and ?60 minutes 
D. Headache fulfilling criteria B-D for 1.1 migraine without aura begins during 
the aura or follows aura within 60 minutes 
E. Not attributed to another disorder 
a When the patient falls asleep during migraine and wakes up without it, 
duration of the attack is reckoned until the time of awakening. 
b Migraine headache is commonly bilateral in young children; the adult pattern 
of unilateral pain usually emerges in late adolescence or early adulthood.
c In young children, photophobia and phonophobia may be inferred from their 
behavior.
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2. Epidemiology of migraine in children
2.1. Prevalence of migraine in children
Before the IHS criteria, many different diagnostic criteria were used, and 
accordingly, the prevalence of migraine varied greatly in epidemiological 
studies. Table 3 provides some prevalence rates of migraine in children and 
adolescents reported in different studies and populations. In general, the 
prevalence of migraine is around 1-3% before schoolage, 4-11% in children 
aged 7-11 years, increasing steadily towards adolescence, being 8-23% in 
those aged 11-15 years (Lewis et al. 2002a). Before puberty, migraine seems 
to be equally common in both sexes, or even slightly more common in boys, 
but during and after puberty more common in girls and women (Abu-Arafeh 
et al. 1994, Lewis et al. 2002a). Boys seem to have onset of migraine at an 
earlier age than girls. In a Finnish study, of 14-year-old boys with migraine, 
one-third had their first attack before school age and two-thirds during the 
first six school years. In girls, only one-fifth had their first attack before 
school age and four-fifths at the age of 8-14 years (Sillanpää 1983).
The prevalence of migraine in children and adolescents has increased during 
the last 10-20 years. In a large Finnish population-based follow-up study of 
children starting school at the age of seven years, conducted in 1974, 1992, 
and 2002 with identical study methods, the incidence of migraine increased 
from 19.7 (per 1000 person-years) in 1974 to 58.6 in 1992, and further to 
133.2 in 2002. The trend was similar in boys and girls (Anttila et al. 2006). In 
this study, the older Vahlqvist´s diagnostic criteria, which are less restrictive 
than IHS criteria (Metsähonkala et al. 1994), were used (Vahlquist 1955). 
Migraine frequency in 2002, reported also by using the updated version of 
IHS criteria, was 114.4 per 1000 person-years. The Authors commented that 
had the IHS criteria been used all three years, the overall incidence rates 
would likely have been slightly lower, but an increasing trend would still 
have been apparent. An American study reported a similar increasing trend of 
migraine prevalence between 1979 and 1981, and between 1989 and 1990 for 
all age groups (0-99 years) in female subjects, but only a slight increase in 
incidence rates for male subjects aged 10-19 years (Rozen et al. 1999).
Review of the literature
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Table 3. One-year prevalence of migraine (lifetime prevalence in ´Bille 1962´) in 
population-based studies. 
Author and  year Country Sample size Age (years) Prevalence (%) 
Bille 1962 Sweden 4440 boys 
4553 girls 
7-15 3.3 
4.4 
Sillanpää 1983 Finland 1473 boys 
1448 girls 
1473 boys 
1448 girls 
7
14
2.9 
2.5 
6.4 
14.8 
Mortimer et al. 1992b United 
Kingdom 
1083 3-11 3.7 
Abu-Arefeh et al. 
1994 
United 
Kingdom 
888 boys 
866 girls 
84 boys 
85 girls 
79 boys 
69 girls
5-15 
7
13
9.7 
11.3 
2.8 
4.1 
14.8 
23.7 
Barea et al. 1996 Brazil 272 boys 
266 girls 
10-18 9.6 
10.3 
Anttila et al. 2002 Finland 1135 12 13.6 
Özge et al. 2003 Turkey 5562 8-16 10.4 
Laurell et al. 2004 Sweden 685 boys 
686 girls 
7-15 9.8 
12.2 
Zwart et al. 2004 Norway 2811 boys 
3036 girls 
13-18 4.8 
9.1 
2.2. Inheritance of migraine
An important aspect of the pathology of migraine is the inherited nature of 
this disorder. It is clear from clinical practice that many patients have first-
degree relatives who also suffer from migraine (Goadsby 2005) and many 
published studies also have report familial occurrence of migraine (Russell 
1997). The familial occurrence of disease is assumed to be either due to 
shared genes, or shared environmental factors, but the high prevalence of 
migraine could also cause familial aggregation simply by chance (Russell et 
al. 1995, Merikangas 1996). The importance of genetic and environmental 
factors in migraine with aura (MA) has been investigated by using family and 
twin study designs. A Danish study included 1013 monozygotic and 1667 
dizygotic twin pairs of the same gender. The pairwise concordance rate of 
MA was significantly higher among monozygotic (34%) than dizygotic 
(12%) twin pairs, emphasizing the importance of genetic factors in MA. 
However, environmental factors also played a role, as the pairwise 
concordance rate was less than 100% in monozygotic twin pairs. The risk of 
Review of the literature
17
MA in dizygotic twins (21%) was similar to the recurrence risk in nontwin 
siblings (27%). The importance of both genetic and environmental factors in 
MA indicates that a multifactorial inheritance is most likely (Ulrich et al. 
1999).
In a Danish family study, the first-degree relatives of subjects with MA had 
nearly a fourfold risk of MA, but no risk of migraine without aura (MO). The 
first-degree relatives of subjects with MO had 1.9 times the risk of MO and 
1.4 times the risk of MA. The first-degree relatives of subjects who had never 
had migraine had no increased risk of MA or MO. Spouses of subjects with 
MO had 1.4 times the risk of MO, whereas spouses of subjects with MA had 
no increased risk of MA. These different familial patterns indicate that MO 
and MA have different etiologies. MO seems to be caused by a combination 
of genetic and environmental factors, whereas MA is probably largely 
determinated by genetic factors (Russell et al. 1995).
3. Pathogenesis of migraine 
The pathogenesis of migraine is incompletely understood, although advanced 
research methods, such as functional neuroimaging, and basic neuroscience 
studies have yielded a large amount of new information in recent years. 
Migraine is best understood as a form of neurovascular headache, a disorder 
in which neural events result in the dilatation of blood vessels, which in turn 
lead to pain and further nerve activation (Goadsby et al. 2002). All symptoms 
of a typical migraine headache cannot be explained by a single theory. 
Migraine is probably most accurately considered a heterogeneous disorder 
with multiple mechanisms involved in its pathogenesis. The underlying 
pathophysiology of childhood migraine is presumably the same as in adults, 
although no research data on this topic exist (Winner 2008).    
3.1. Migraine aura 
Migraine aura is believed to be caused by a phenomenon known as cortical 
spreading depression (CSD), first described by Leao in 1944. According to 
this theory, when the human cortex is activated, a wave of neuronal 
excitation followed by depression starts to spread along the cortex at a 
velocity of 2-3 mm/min. CSD is characterized by shifts in cortical steady-
state potential, transient increases in potassium, nitric oxide (NO), and 
glutamate, and transient increases in cortical blood flow, followed by 
sustained flow decreases. This is manifested clinically as migraine aura 
(Olesen et al. 1990, Kramer et al. 1998, Silberstein 2004). The initial 
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hyperemic phase is followed by reduced cortical blood flow, which moves 
across the cortex (spreading oligemia) (Olesen et al. 1981). The rate of 
progression of spreading oligemia is similar to rates of migraine scotoma and 
CSD, suggesting that they are related (Pietrobon et al. 2003). During visual 
aura the cortical blood flow decreases by 15-53% and the mean transit time 
increases 10-54% in the occipital cortex contralateral to the aura. This 
perfusion defect moves anteriorly (Cutrer et al. 1998). The occipital cortex is 
especially sensitive to spreading depression, which explains why visual 
scotoma is the most common form of migraine aura (Wray et al. 1995).  
3.2. Migraine headache 
The trigeminal nervous system, which innervates the cranial vasculature, and 
its reflex connections with the cranial parasympathetics form the 
trigeminoautonomic reflex. This is thought to be essential in the pathogenesis 
of migraine headache (Goadsby et al. 2002, Silberstein 2004). Activation of 
the trigeminal nucleus caudalis in the brainstem and trigeminal afferent fibers 
that innervate large cerebral vessels, pial vessels, large venous sinuses, and 
duramater is thought to cause perivascular release of vasoactive 
neuropeptides, such as substance P, calcitonin gene-related peptide, 
neurokinin A, and nitric oxide (NO). Neuropeptides interact with the blood 
vessel wall, producing neurogenic inflammation, vasodilatation, plasma 
protein extravasation, and platelet activation. This leads to central 
transmission of pain information, and further to migraine headache. 
Activation of autonomic tracks of the trigeminovascular system produce the 
associated symptoms of migraine, e.g. nausea and vomiting  (Ferrari 1998, 
Pietrobon et al. 2003, Silberstein 2004). Neurogenic inflammation sensitizes 
nerve fibres, and they start to respond painfully to previously innocuous 
stimuli, such as blood vessel pulsations, and other normal activity, such as 
coughing. This is called peripheral sensitization and partly causes the 
throbbing headache of migraine (Strassman et al. 1996, Pietrobon et al. 
2003). Central sensitization can also occur. Cutaneous allodynia (exaggerated 
skin sensitivity), which is frequently seen during migraine attacks, is thought 
to be caused by trigeminal sensitization (Burstein et al. 2000). The absence of 
cutaneous allodynia may be crucial in reaching positive outcome from triptan 
treatment (Burstein et al. 2004). 
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3.3. Why aura leads to headache
Bolay et al. (2002) were the first to show the pathophysiological connection 
between migraine aura and headache in rodents (Figure 1) (Bolay et al. 2002, 
Iadecola 2002). How accurately this rodent model mimics the human disease 
is, however, unclear. Aura does not appear to be an absolute requirement for
headache, as in most patients headache is not preceded by aura.
Figure 1. Theory of the relationship between cortical spreading depression (CSD) and
headache in migraine with aura. CSD was demonstrated to release hydrogen ions (H+),
potassium ions (K+), arachidonic acid (AA), and nitric oxide (NO) into the extracellular
space of the neocortex. According to this theory, these agents diffuse towards local blood 
vessels, depolarize perivascular trigeminal terminals, and cause activation of the caudal
portion of the trigeminal nucleus (TGN) in the brainstem. At the same time, collateral axons
of activated neurons in the trigeminal ganglion (TGG) release pro-inflammatory peptides in
the meninges and their vessels, leading to a local inflammatory reaction. The activation of 
TGN, caused by CSD, produces vasodilatation of meningeal blood vessels through a 
pathway originating from the superior sagittal sinus (SSN) in the brainstem, and reaches the
meningeal blood vessels via the sphenopalatine ganglion (SPG). The perception of pain is
mediated by higher-order projections from the TGN. The dashed lines indicate unknown
connections. Modified from Iadecola (2002).
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3.4. Serotonin in migraine
The most effective drugs currently used for acute as well as prophylactic 
treatment of migraine are known to work through serotonin (5-
hydroxytryptamine, 5-HT) receptors, implying that serotonin is an important 
factor in migraine pathogenesis. Serotonin acts mostly as an inhibitory 
neurotransmitter. There are seven classes of 5-HT receptors (5-HT1-7) (Hoyer 
et al. 1994) and five 5-HT1 receptor subtypes (5-HT1A, 5-HT1B, 5-HT1C, 5-
HT1D, and 5-HT1F) (Hartig et al. 1996) that mediate pre- and postsynaptic 
inhibition. The 5-HT1B, 5-HT1D, and 5-HT1F receptors are associated with the 
treatment of migraine with triptans and ergotamines. The 5-HT1B receptors 
are located in cranial vasculature, whereas the 5-HT1D and 5-HT1F receptors 
are located in trigeminal nerve endings (Longmore et al. 1997). Serotonin can 
have varying effects on vessel tone, causing either vasodilatation or 
vasoconstriction. Vasoconstriction is mediated by receptors in the 5-HT1 and 
5-HT2 families. Excitatory effects of serotonin are mediated by the 5-HT3
receptors, which have a role in nociception and vomiting (Schwedt 2007). 
Serotonin is degraded by monoamine oxidase (MAO) into a reactive 
aldehyde, which is further processed by aldehyde dehydrogenase into the 5-
HT primary metabolite, 5-hydroxyindoleacetic acid (5-HIAA). The serotonin 
transporter (SERT) is responsible for presynaptic reuptake of serotonin. 
Drugs such as the selective serotonin inhibitors have high specificity for 
blocking serotonin reuptake by SERT (Schwedt 2007). In the brain, serotonin 
is stored within synaptic vesicles. When 5-HT neurons are depolarized, 
serotonin release occurs through Ca2+-dependent exocytosis, which is 
dependent on the firing rate of serotonergic neurons. Therefore, release of 
serotonin is decreased by drugs that reduce the firing rate of serotonergic 
neurons, e.g. agonists of presynaptic 5-HT1A or 5-HT1B auto-receptors. After 
serotonin is released, it is either metabolized into 5-HIAA or decapsulated 
into serotonergic neurons by SERT. These mechanisms are essential for the 
maintenance of serotonin homeostasis (Hamel 2007).  
Multiple studies of the serotonergic system in the context of migraine have 
been published. The results are contradictory, but a few trends have been 
noted. Plasma serotonin levels were altered in subjects with migraine. 
Between attacks, serotonin levels were lower, whereas 5-HIAA levels were 
higher, than in nonmigraine controls. During migraine attacks serotonin 
levels increased, while 5-HIAA levels decreased (Ferrari et al. 1989). The 5-
HIAA concentrations in urine increased during migraine attacks (Sicuteri et 
al. 1961). There is also evidence that brain serotonin synthesis is increased in 
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patients with migraine (Chugani et al. 1999), and 5-HIAA concentrations are 
elevated in the cerebrospinal fluid of migraine patients, suggesting increased 
breakdown of serotonin in the CNS (Kovacs et al. 1989). These observations 
have led to the hypothesis that a chronically low serotonin disposition could 
form a biochemical basis of migraine pathogenesis and that a sudden increase 
in serotonin release could be one of the triggering events leading to migraine 
attack (Hamel 2007).
3.5. Genetics of migraine 
Although family and twin studies show that a genetic component is present in 
migraine, no genes predisposing to MA or MO have been identified. Family-
based linkage studies have elucidated several chromosomal regions linked to 
these common forms of migraine, but there is little consistency between the 
studies (Wessman et al. 2004, 2007). The most encouraging approach has 
been the identification of genes causing a rare migraine subtype, familial 
hemiplegic migraine (FHM), which is inherited as an autosomal dominant 
trait with incomplete penetrance. The first locus linked to FHM was mapped 
to chromosome 19p13 (Joutel et al. 1993), and later, the first mutations in the 
voltage-gated calcium channel CACNA1A-gene in that area were identified 
(Ophoff et al. 1996). Mutations in this gene are responsible for about 50% of 
the identified FHM families, now known as FHM-1 (Ducros et al. 2001). 
Since then, mutations also on chromosome 1q21-23 in the ATP1A2 gene, 
encoding the Na+, K+-ATPase, were identified. This mutation is thought to be 
responsible for about 20% of the FHM families (FHM-2) (Ducros et al. 1997, 
De Fusco et al. 2003, Marconi et al. 2003). No definitive phenotypic 
differences exist between FHM-1 and FHM-2. The penetrance is possibly 
somewhat lower for FMH-2, and cerebellar signs are mostly associated with 
FMH-1 (Ducros et al. 2001). Recently, a third locus and gene for FHM, 
SCN1A on chromosome 2q24, has been identified. This codes for a neuronal 
voltage-gated sodium channel, and mutations in it have previously been 
associated with different epilepsy phenotypes (Dichgans et al. 2005).
The main symptoms of FHM are very similar to those of MA. Cortical 
hyperexcitability followed by increased susceptibility to cortical spreading 
depression (CSD) are suggested as the underlying shared pathophysiological 
mechanism of symptoms. Since Cav2.1 channels play a major role in the 
release of excitatory neurotransmitter glutamate from cortical neurons, 
increased Ca2+ influx through mutant channels could lead to hyperexcitability
(Moskowitz et al. 2004). In accordance with this hypothesis, CACNA1A 
R192Q knock-in mice show a decreased threshold for CSD (van den 
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Maagdenberg et al. 2004). Cav2.1 channels were also demonstrated to have a 
role in modulating trigeminal nociception (Knight et al. 2002). Although no 
convincing evidence exists of an association between CACNA1A, ATP1A2, 
or SCN1A and MA or MO, some clinical features (e.g. episodic occurrence 
of symptoms and existence of triggering factors) support the hypothesis that 
the common forms of migraine could also be channelopathies (Ptacek 1998). 
All three FHM genes point to the importance of cell membrane ion-potential 
balance, which seems to also be the case with other paroxysmal disorders 
such as epilepsy and cardiac arrhythmias (Hubner et al. 2002). Pathways 
involving products of these genes remain the top candidates for underlying 
causes of  migraine pathogenesis (Wessman et al. 2004, 2007). 
4. Characteristics of migraine in children and adolescents 
4.1. Migraine headache 
Migraine is a severe, often throbbing headache that is frequently located 
unilaterally in the temples or frontal head regions in adults. In children, the 
head pain is more often bilateral, located in the central forehead or the frontal 
area. During a migraine attack, a child will often look ill and pale. The 
headache is remarkably severe, and 44% of children under eight years of age 
and 59% of those over eight years report that they at least occasionally cry 
because of migraine headache. About 40% of all children have missed school 
or playschool due to migraine (Mortimer et al. 1992a). Nausea and vomiting 
are frequent, particularly in younger children. Patients avoid bright lights, 
loud noise, and strong odors. Headache is typically aggravated by movement 
and relieved by lying down in a dark room or sleeping.  
4.2. Migraine aura 
Approximately, one-third of affected children have migraine with aura. Aura 
is slightly more infrequent in children under eight years of age (Mortimer et 
al. 1992a). The typical aura is binocular visual impairment with scotoma 
(77%), distortion or visual hallucination (16%), or monocular visual 
impairment or scotoma (7%) (Hachinski et al. 1973). Formed illusions (e.g. 
spots, balloons, colors, rainbows), hemianopia, blurred vision, or micropsia 
have also been described (Lewis 2007). Other less common auras consist of 
sensory symptoms or focal motor deficits (hemiplegia). Aura usually 
precedes the headache by less than 30 minutes, lasts 5-20 minutes, and 
subsides when the headache appears. Child can also have premonitory 
symptoms before the attack onset. Mood changes were experienced by 47% 
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of children 24 hours before attack onset; 64% of these were inhibitory and 
36% excitatory. Premonitory symptoms were slightly more often observed in 
children under eight years of age (Mortimer et al. 1992a). 
4.3. Frequency and duration of migraine attacks 
Attack frequency and duration often increase with age. In children aged 
under 14 years, 75% had one or more attacks per month, the median 
frequency being one per week. The median duration of attack was five hours 
in children under 14 years of age, and nine hours in those aged 15 or older 
(Wöber-Bingöl et al. 2004). A British study reported a mean frequency of 6.8 
attacks in the previous year in children aged 3-7 years, and the mean attack 
duration of MA and MO being 7.9 and 18.1 hours, respectively. In older 
children aged 8-11 years, the mean attack frequency was 11.3 attacks, and the 
mean attack duration of MA and MO was 13.1 and 17.8 hours, respectively 
(Mortimer et al. 1992a). In a Finnish study of 3-17-year-old children, 96% 
reported having at least one attack per month, with a median duration of 12 
(range 2-96) hours (Hämäläinen et al. 1996). Short attacks, lasting less than 
two hours, were experienced by 5.9% of British children under eight years of 
age and by 11% of those older than eight years (Mortimer et al. 1992a). A 
combination of short (<1 hour) and longer (>2 hours) attacks can coexist in 
the same patient (Abu-Arafeh et al. 2004).   
4.4. Rare subtypes of migraine 
In addition to migraine with or without aura, some rare subtypes of migraine 
occur also in children.
Basilar migraine represents 3-19% of childhood migraines. The mean attack 
onset age is seven years. These attacks are characterized by episodes of 
dizziness, vertigo, visual disturbances, ataxia, or diplopia, followed by a 
headache that is often occipital. The benign paroxysmal vertigo in young 
children with abrupt episodes of unsteadiness or ataxia, sometimes 
nystagmus or pallor, dizziness, and nausea may precede the onset of 
migraine, as in long-term follow-up many children with these symptoms 
eventually develop basilar migraine (Lewis 2007).  
Confusional migraine is a migraine variant that has perceptual distortions as 
its main feature. Affected patients, often boys, abruptly become agitated, 
restless, disorientated, and sometimes aggressive. The confusion phase may 
last minutes to hours. Once consciousness returns to baseline, the patients 
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describe an inability to communicate, frustration, confusion, and a loss of 
orientation to time, and they may not recall any headache phase (Lewis 
2007).
Ophthalmoplegic migraine is nowadays categorized under cranial neuralgias, 
instead of the migraine spectrum. The main feature is painful 
ophthalmoparesis, but the pain may not be severe. Ptosis, limited adduction, 
and vertical displacement (as with involvement of the 3rd cranial nerve) are 
the most common findings. The oculomotor symptoms and signs may appear 
during the headache phase rather than preceding the headache. The signs may 
persist for days or even weeks after the headache has resolved (Lewis 2007).
Familial hemiplegic migraine (FHM) is an autosomal dominant form of 
migraine, as described earlier in Section 3.5. Clinically, FHM is a migraine 
headache preceded by an aura that has stroke-like qualities, producing some 
degree of hemiparesis. These transient episodes of focal neurologic deficits 
precede the headache by 30 to 60 minutes, but occasionally continue hours to 
days after the headache has resolved. The location of the headache is often 
contralateral to the focal deficits (Lewis 2007).
Abdominal migraine is characterized by episodic, vague, midline, or 
periumbilical abdominal pain. Abdominal migraine includes a group of 
patients who have chronic, recurrent abdominal pain and features that overlap 
with those of migraine without aura. Abdominal migraine generally occurs in 
schoolaged children, who report recurrent attacks of dull midline or upper 
abdominal pain that generally lasts for hours (Lewis 2007).
4.5. Prognosis 
Childhood migraine, especially in boys, is thought to have a good prognosis, 
although longitudinal studies are very few. Migraine that begins before 
schoolage is reported to disappear more often in boys than in girls, but when 
migraine begins at the age of 8-14 years, it has better prognosis in girls than 
in boys. Of those children who at the age of seven years suffered from 
migraine, attacks disappeared entirely in 22%, were alleviated in 37%, and 
remained unchanged or became more severe in 41% by the age of 14 years 
(Sillanpää 1983).
In a Swedish 40-year follow-up study, 23% of childhood migraine patients 
with a mean attack onset age of six years were permanently migraine-free at 
puberty or as young adults (between 13 and 25 years). Males were 
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significantly more often migraine-free (34%) than females (15%). In 
addition, 22% of patients had been migraine-free for more than two years by 
that time, but relapsed later and continued to have attacks occasionally, with 
some migraine-free years in between. In their thirties, 40% of patients were 
migraine-free, but 38% still had annual attacks. Gender differences were no 
longer present. In their forties and fifties, 47% and 46% of patients were 
migraine-free, respectively, but over 50% continued to have at least 
occasional attacks (Bille 1997).  
A similar prognosis was reported in a 20-year follow-up study done in 
Canada in children and adolescents, whose mean age at the time of diagnosis 
(study onset) was 11 years. Ten and 20 years later, 60% and 53% of patients, 
respectively, continued to have migraine attacks (Brna et al. 2005).
5. Diagnosis of migraine in children and adolescents
Headache is a common complaint in children and adolescents, and may be a 
symptom of a broad range of illnesses from the common cold to intracranial 
neoplasm. There is no specific diagnostic test for migraine. The diagnosis is 
based on taking a careful patient history, collecting detailed information 
about headache characteristics, and performing a clinical examination, to 
exclude possible other causes of recurrent headache. This usually requires a 
period of observation (at least 6 months), during which it can be established 
that the child is otherwise well, and growth and development continue 
normally. A headache diary is a useful tool during the follow-up period. A 
combination of features is required for the diagnosis of migraine (diagnostic 
criteria; Table 2), but not all features are present in every attack or in every 
patient (Goadsby et al. 2002). Additional diagnostic tests are needed only 
rarely.  
Laboratory tests. The American Academy of Neurology states in the 
Practice Parameters for Physicians that there is no adequate documentation in 
the literature supporting the appropriateness of any routine laboratory tests or 
routine lumbar puncture in the evaluation of recurrent headache in children 
(Lewis et al. 2002a). They usually do not reveal any clinically relevant 
diagnostic information, and these tests should therefore be done only when 
clinically assessed to be necessary.
Electroencephalogram (EEG). Data from four studies in children with all 
kinds of recurrent headaches and from four studies in children with migraine 
demonstrated that EEG was either normal or demonstrated nonspecific 
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abnormalities in most patients. In four studies with migraine patients (n=219 
children), 47% had normal EEG, 25% had spike activity, 11% had diffuse 
slowing, and 27% had other abnormalities. In four studies with all kinds of 
recurrent headaches (n=929), 75% of patients had normal EEG, 13% had 
spike activity, 7% had diffuse slowing, and 5% had other abnormalities. 
There was no significant difference in EEG findings in children with 
migraine compared with those with all kinds of recurrent headaches. The lack 
of a difference could be due to 44% of those patients with all kinds of 
headaches being diagnosed with migraine. No evidence supported that EEG 
findings would be sufficient in either specificity or sensitivity in individual 
patients to be clinically useful in the diagnostics of migraine. Furthermore, 
none of these eight studies reported any patients who subsequently developed 
new-onset seizures after clinical evaluation for headaches, even when the 
EEG showed paroxysmal abnormalities. These findings can be summarized 
as follows: in patients with abnormal EEG, there was no indication that this 
EEG finding provided any diagnostic information about the etiology of 
headache. Therefore, routine EEG is not recommended as part of the 
headache evaluation (Lewis et al. 2002a).
Neuroimaging studies. Routine neuroimaging is not indicated for children 
with recurrent headaches if the findings in neurological examination are 
normal. Data on 605 of 1275 children from six studies of children with 
recurrent headaches who were examined by a neurologist and underwent 
neuroimaging revealed only 14 patients (2.3%) with nervous system lesions 
requiring surgical treatment. All 14 children had definite abnormalities on 
examination. No patient with a normal examination had a lesion requiring 
surgical treatment.  If there are clinical abnormalities, such as focal findings, 
signs of increased intracranial pressure, alteration of consciousness or patient 
temper, or coexistence of seizures, neuroimaging should be considered. 
Neuroimaging should also be considered if recent onset of a severe headache, 
change in the type of headache, or neurologic dysfunction occurs (Lewis et 
al. 2002a, Lewis 2007).   
6. Predisposing factors for migraine 
Children may be predisposed to migraine by both genetic and environmental 
factors. Population-based family and twin studies suggest that about half of 
the variance in migraine prevalence is explained by genetic factors, which 
leaves a strong role for environmental factors (Bigal et al. 2007).
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6.1. Psychosocial factors
In the literature, abundant studies have investigated the effect of psychosocial 
factors on the prevalence of childhood headache in general, however, these 
usually have not distinguished migraine from tension-type headache (TTH) 
or other headache types. Psychosocial factors are generally thought to be 
more relevant in TTH than in migraine (Karwautz et al. 1999), but many 
contradictory findings also exist.
In adults, migraine prevalence was higher in the population with lower 
income and lower education level (Lipton et al. 2007). In American 
adolescents older than 12 years, low household income was associated with 
higher prevalence of migraine. However, in adolescents with a strong family 
history of migraine, household income did not have a significant effect, 
probably because of the higher biologic predisposition (Bigal et al. 2007). 
Factors associated with low socioeconomic status, such as stress, poor diet, or 
limited use of medical care, may increase migraine prevalence in adults 
(Wadsworth et al. 2005), but in children environmental risk factors associated 
with low income are unclear.  
In a Finnish study, children with migraine lived in more unhappy (and more 
often poor or very poor) families, with family members having more long-
term illnesses and paroxysmal headaches than children with other types of 
headache. Children with migraine more often had fear of failure at school and 
a fear of teachers, but no difference existed in bullying, behavior problems, or 
learning difficulties in migraine patients compared with those with other 
kinds of headaches (Anttila et al. 2000). An earlier Finnish study reported 
that stress in school was strongly associated with migraine in 8–9-year-old 
girls, but problems in peer relationships were most strongly associated with 
migraine in boys of the same age (Metsähonkala et al. 1998).
An Austrian study reported that migraine patients were more often absent 
from school due to headache than patients with TTH, but patients with TTH 
experienced more psychosocial stress factors than migraine patients and 
headache-free controls. Migraine patients did not differ from headache-free 
controls in any environmental factors investigated (Karwautz et al. 1999). 
Children with migraine were reported to have more emotional disorders 
(anxiety, depression, or other neurotic disorder) than children with 
nonmigrainous headache (Marates et al. 1982, Guidetti et al. 1998). A 
Canadian study described no difference between children with migraine and 
headache-free controls in anxiety or stressful life events scores. However, 
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41% of children with migraine and 46% of their parents cited stress as a 
major trigger of migraine attack (Cooper et al. 1987).
6.2. Effect of diet
Evaluation of the role of diet in migraine is complex because multiple 
triggers and variables may modify an individual´s threshold to pain. Dietary 
factors may, at least in some patients, have an influence on frequency of 
migraine attacks. More important, however, is to maintain a well-balanced 
diet, without fasting or skipped meals, as 20-25% of children report 
headaches associated with a missed meal (Leviton et al. 1984). In patient-
based studies, including both adults and children, the percentage of migraine 
patients reporting a particular food or drink as a precipitant of an attack has 
varied from 7% to 44%. In children, cheese, chocolate, and citrus fruit were 
the principal dietary attack triggers (van den Bergh et al. 1987, Millichap et 
al. 2003). 
A biogenic amine, tyramine, is found in aged cheese and in many other foods 
and beverages, including wine, beer, beans, and sauerkraut. Normally, 
ingested tyramine is metabolized by MAO in the gut and liver and conjugated 
by enzymes so that it fails to enter the systemic circulation. Patients with 
dietary migraine are thought to have a deficiency in this metabolizing system 
such that tyramine is absorbed from the gut into the circulation, causing a 
headache via its vasoconstrictor effects (Smith et al. 1971).  
The ingredients in chocolate implicated in the mechanisms of dietary-
triggered migraine include phenylethylamine, theobromine, caffeine, and 
catechin. These chemicals may initiate a headache by altering cerebral blood 
flow and releasing norepinephrine from sympathetic nerve cells (Millichap et 
al. 2003).
Abrupt withdrawal from caffeine after regular consumption of large amounts 
may lead to headaches and exacerbation of migraine. This is thought to occur 
because of rebound vasodilatation and increased arterial blood flow when 
caffeine is discontinued after cerebral vasoconstriction during caffeine intake 
(Couturier et al. 1997). Children and adolescents sometimes consume large 
volumes of caffeine-containing carbonated drinks daily. Those children who 
consume 200 mg (e.g. 1.5 liters of cola drinks) or more of caffeine daily may 
be at risk of caffeine-induced or caffeine withdrawal headache (Hering-Hanit 
et al. 2003).
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Even in moderate amounts of alcohol can trigger a migraine headache in 
susceptible patients. Tyramine, histamine, phenolic flavonoids, and sulfites 
are generally involved in the induction of migraine headache by various 
mechanisms, and are found particularly in red wines (Peatfield 1995).
Patients with migraine often complain of headache related to eating ice cream 
or other frozen foods. This is probably a cold-induced vasoconstrictor reflex 
response that is not specific to migraine sufferers (Millichap et al. 2003). 
Nitrites found e.g. in sausages can function as a chemical migraine trigger. 
Monosodium glutamate is found in many Asian dishes. It is a potent 
vasoconstrictor and can cause a group of symptoms known as the 
monosodium glutamate symptom complex (including headache, flushing, 
paresthesias, sweating, palpitation, and facial swelling), also known as the 
´Chinese restaurant syndrome´ (Millichap et al. 2003). In addition, many 
other chemicals have been reported to predispose to migraine attacks. 
7. Sleep and migraine 
Sleep and migraine are related in many respects. There are several reports of 
sleep disturbances in children and adolescents with migraine. Besides 
psychiatric problems, sleep disturbances are the most frequent complaint in 
children with headaches (Guidetti et al. 1998). Children and adolescents with 
migraine have described having poorer sleep quality and more difficulties in 
falling asleep, night awakenings, daytime sleepiness, and nocturnal 
symptoms, such as sweating, sleep-talking, bruxism, sleepwalking, and 
nightmares, than headache-free controls (Bruni et al. 1997, Miller et al. 2003, 
Heng et al. 2006, Isik et al. 2007). In adolescents with migraine, both 
frequency and intensity of headache, as well as duration of headache history, 
were related to the occurrence of sleep disturbances (Gilman et al. 2007). All 
studies agree that it remains unclear whether the occurrence of migraine 
headache leads to specific sleep disturbance, whether sleep disturbance leads 
to or contributes to headaches, or whether sleep disturbance and migraine 
headaches are components of separate clinical syndromes. In any case, bad 
sleep was reported to be the most frequent triggering factor for migraine 
attacks in children (Bruni et al. 2007). Further, in children and adolescents 
who were able to attain better sleeping habits by being instructed on how to 
improve their sleep hygiene, the mean duration and frequency of migraine 
attacks were significantly reduced compared with children with migraine 
who did not receive sleep hygiene guidance (Bruni et al. 1999).
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Some clinical, anatomical, biochemical, and physiological evidence supports 
an inherent association between the normal physiology of sleep and a genesis 
of migraine in biologically predisposed individuals (Dodick et al. 2003). This 
theory hypothesizes a close relationship between the hypothalamus and 
brainstem in controlling physiological sleep and a role of hypothalamus in 
maintaining a circadian rhythm with melatonin. The hypothalamus has  input 
and output connections to noradrenalin and serotonin repositories in the locus 
ceruleus and the dorsal raphe in the brain stem, which are thought to be 
involved in the pathogenesis of migraine. Melatonin might have some 
analgesic effect on headache. It increases the inhibitory action of gamma-
aminobutyric acid (GABA), and thus, raises the threshold of pain circuits. 
Further, it inhibits the synthesis of prostaglandin E2, modulates the entry of 
calcium into cells, diminishes the vasoreactivity of cerebral blood vessels, 
and can modulate 5-HT2 receptors on cerebral arteries (Morgan et al. 1994). 
Both urinary and plasma melatonin were decreased in patients with migraine 
(Brun et al. 1995). 
Sleep has an important role in the natural healing process of migraine attack. 
This has recently been reflected in the diagnostic criteria of migraine: if a 
patient falls asleep during an attack, this sleeping time is considered as part of 
the attack duration (Headache Classification Committee of the International 
Headache Society 2004). Although the role of sleep in the recovery phase of 
migraine attack has clinically clearly been observed, scant published data 
exist on this for both adults and children. The role of sleep in recovery from 
migraine attack was studied in 310 adults. Half of the patients fell asleep 
within three hours after taking medication, and the other half was rested 
without sleep. Of those who fell asleep, 50% had a full recovery, while the 
same was true for only 31% of the control group (Wilkinson et al. 1978). In a 
sample of 1283 adult migraine patients, 85% reported that they chose to sleep 
because of headache, and 75% were forced to sleep or rest because of 
headache. Of these same patients, 50% reported that their migraine attacks 
are triggered by sleep disturbance, and they experience headaches that 
awaken them from sleep (Kelman et al. 2005). In a study of 50 adults with 
migraine, 14 could shorten their attacks by going to sleep for an average of 
2.5 hours (Blau 1982). 
Sleep seems to be a very important factor in the healing process of childhood 
migraine. Resting is probably the most common nonpharmacological way of 
trying to relieve migraine headache in children, who generally prefer 
nonpharmacological treatments over pharmacological ones more often than 
adults. In fact, resting was cited as the primary treatment choice by 28% of 
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Canadian children with migraine (Dooley et al. 1995). In a study of 34 
migraine patients aged 10-17 years, 74% of patients slept during an attack, 
and 56% were asleep within 30 minutes of attack onset. Their duration of 
sleep was between 0.5 and 16 hours, and when waking up, nearly 20% had 
no headache and 69% were markedly improved (Massiou 1997).   
Sleeping is also relevant in clinical drug trials. The question is repeatedly 
raised of how the results of a child who sleeps during a migraine attack 
should be handled. Should sleeping be taken as a sign of positive effect of the 
study drug, or should the results of such children be omitted from analyses. 
The latter option has the risk of skewing the results, as sleeping occurs so 
frequently. The European Medicines Agency´s (EMEA) Committee for 
Medicinal Products for Human Use has recommended in its recent ´Guideline 
on clinical investigation of medicinal products for the treatment of migraine 
in children and adolescents´ that falling asleep at two hours after the study 
agent (with no use of rescue medication and no relapse within 48 hours) 
could be used as an efficacy endpoint in studies of acute treatment of 
migraine in children (European Medicines Agency 2006).   
8. Assessment of pain in children
Pain assessment, especially in young children, is a challenging task for the 
clinician. As pain is a subjective experience, self-reported scales are the gold 
standard in pain assessment and are wildly used and validated in adults 
(Sriwatanakul et al. 1983, Littman et al. 1985). By contrast, children have 
limited cognitive and expressive abilities compared with adults, which leads 
to a special need for self-reporting tools appropriate for children and their 
stage of cognitive development.     
More than forty measurement tools designed for use in children have been 
published (Hicks et al. 2001). For patients younger than three or four years, 
pain assessment methods are primarily based on observation. These comprise 
physiological measures, including the analysis of such vital signs as change 
in blood pressure and heart rate, and behavioral measures that reflect, for 
example,  the child´s vocalization, movements, irritability and rigidity of the 
limbs and body (Berde et al. 2002).  
From the age of 3-4 years, a child can usually express pain with facial scales, 
which include sequential drawings or photographs of faces showing different 
levels of pain intensity. To use this tool, the child needs the cognitive 
capacity to match pictures of facial expressions to his/her internal state 
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(Hicks et al. 2001). The child does not need to be able to count or to use 
numbers in a categorical fashion, but a basic understanding of the concept of 
ordering is required. Different versions of these scales have been 
demonstrated to be valid and reliable in measuring pain in children (Belville 
et al. 2005). Face scales were preferred to various other scales in all pediatric 
age groups (Hicks et al. 2001). Color analog scales, i.e. a line with increasing 
intensity of red color signifying increasing intensity of pain, can also be used 
for children of 3-8 years (McGrath et al. 1996). Good agreement was 
reported between face scale and color analog scale in children aged 3-7 years 
after surgery (Beyer et al. 1990).
From the age of 7-8 years, a child can often adequately use visual analog 
scales (VASs). The VAS includes a horizontal line of varying length (often 
10 cm), with no pain at one end and the worst possible pain at the other end. 
The patient chooses the point on the line that best expresses the intensity of 
pain experienced. The VAS is validated and is the most frequently used pain 
scale in adults and adolescents (Belville et al. 2005).
9. Treatment of migraine in children
As in adults, treatment of migraine in children and adolescents can be divided 
into nonpharmacological and pharmacological treatments. Pharmacological 
treatments can further be divided into acute attack treatment and prophylactic 
treatment, the latter referring to a daily treatment to prevent frequently 
recurrent migraine attacks.   
9.1. Acute treatment
9.1.1. General principles
Although resting without a drug may bring sufficient relief in mild migraine 
attacks, drug treatment is usually needed. The dose should be sufficient and 
in a rapidly absorbable form, ideally administered as the first symptoms of an 
attack appear. Drug treatment should be followed by resting in a dark, quiet 
room. The Finnish Current Care Guideline of Childhood Headache 
recommends paracetamol (15 mg/kg; maximum dose 60 mg/kg/day) and 
ibuprofen (10 mg/kg; maximum dose 40 mg/kg/day) for the acute treatment 
of migraine in children. Paracetamol is slightly more rapid in action but 
complete pain-free response after ibuprofen is two times more likely than 
after paracetamol. Overall, liquid formulations are absorbed faster and 
suppositories slower than tablets (Suomen Lastenneurologinen Yhdistys ry:n 
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asettama työryhmä 2003). If needed, analgesic treatment can be combined 
with metoclopramide (0.1-0.3 mg/kg/day) to prevent vomiting and improve 
gastric motility, as gastric stasis and decreased drug absorption often occur 
with migraine attacks (De Ponti 2000). NSAIDs are not suitable for treating 
very frequent headaches since frequent administration may lead to 
exacerbation of headaches (medication-overuse headache).  
The Practice Parameters for Physicians produced by The American Academy 
of Neurology concludes that ibuprofen is effective and paracetamol probably 
effective, and either can be safely used for the acute treatment of migraine in 
children. Furthermore, nasal sumatriptan was stated as being effective in the 
treatment of adolescents aged over 12 years (Lewis et al. 2004a). Similar 
findings were reported by the American Academy of Pediatrics (Damen et al. 
2005), but a recent meta-analysis of all randomized controlled trials on the 
acute pharmacological treatments of children and adolescents revealed only 
ibuprofen and nasal sumatriptan to be significantly more effective than 
placebo (Silver et al. 2008). All of these medications were well tolerated, but 
significantly more adverse effects were reported for nasal sumatriptan than 
for placebo (Damen et al. 2005).        
9.1.2. Nonsteroidal anti-inflammatory drugs and paracetamol 
Ibuprofen and paracetamol are currently the first-line therapies for childhood 
migraine. These agents are readily available without prescription, are 
inexpensive, and their efficacy and safety have been best established (Lewis 
et al. 2004a). However, only two placebo-controlled studies of their efficacy 
have been published (Hämäläinen et al. 1997c, Lewis et al. 2002b). No 
published placebo-controlled studies exist of any NSAIDs other than 
ibuprofen in children.
Efficacy in children and adolescents. Both paracetamol (15 mg/kg) and 
ibuprofen (10 mg/kg) were effective in relieving migraine attacks in a 
double-blind, three-way, cross-over, placebo-controlled study in 66 children 
aged 4-16 years. Both ibuprofen and paracetamol were superior to placebo in 
relieving headache at one and two hours. At two hours, 68% of children after 
ibuprofen, 54% after paracetamol, and 37% after placebo experienced 
marked pain relief. Complete pain-free response at two hours was reported by 
60% of children after ibuprofen, 39% after paracetamol, and 28% after 
placebo. No significant differences were present in pain relief responses 
between ibuprofen and paracetamol at any time-point. Paracetamol seemed to 
be slightly more rapid in action (at one hour, 39% response vs. 37% response 
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after ibuprofen), but complete pain-free response after ibuprofen was two 
times more likely at two hours than after paracetamol (OR 2.2, 95% CI 1.1-
4.0). No significant adverse effects were reported (Hämäläinen et al. 1997c).  
The efficacy of ibuprofen suspension (7.5 mg/kg) was studied also in a 
parallel, double-blind, placebo-controlled trial with 84 children aged 6-12 
years (Lewis et al. 2002b). Ibuprofen was more effective than placebo at two 
hours, as marked headache relief was reported by 76% of the patients after 
ibuprofen compared with 53% after placebo. At two hours, 44% after 
ibuprofen and 25% after placebo were completely pain-free. The authors did 
not report adverse effects. According to these studies, ibuprofen and 
paracetamol can offer marked headache relief to many children with 
migraine, but one-third need more effective treatments.  
9.1.3. Ergotamine alkaloids 
Ergotamine tartrate, originally derived from a rye fungus (Claviceps 
purpurea), was first isolated from ergot extract in 1918 and was used to treat 
migraine attacks in 1925. Ergotamine tartrate has serotonergic agonist and ?-
adrenergic antagonist activity. Dihydroergotamine (DHE) is a derivative of 
ergotamine with similar receptor actions (Silberstein et al. 1995). The 
bioavailability of ergotamine tartrate is low and highly dependent on the 
route of administration. It can be administrated as a sublingual preparation, 
and in combination with caffeine as an oral tablet and suppository. Caffeine 
enhances its oral and rectal absorption, but absorption is still erratic and 
highly inconsistent between individual patients in all administration routes. 
Ergotamines are prone to produce psychological and physiological 
dependence as well as vasospasms and  ergotamine-overuse and ergotamine-
withdrawal headaches. These in addition to administration problems, 
diminish their usefulness in treatment of migraine (Tfelt-Hansen 2001).  
Efficacy in children and adolescents. One small placebo-controlled cross-
over trial of efficacy of oral DHE (20 μg/kg) in therapy-resistant migraine 
attacks in children aged 6-11 years has been published (Hämäläinen et al. 
1997b). After DHE, seven of 12 children reported at least two-grade pain 
relief on a five-face pain scale, while two of 13 children improved similarly 
after placebo. The efficacy of DHE seemed superior to placebo, although 
statistical significance was not reached, possibly due to the small treatment 
group.
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9.1.4. Triptans 
The group of 5-HT agonists, also called triptans, has revolutionized the 
abortive therapy of migraine attacks in adults over the past 15 years. With 
their specific mode of action, these drugs can alleviate also systemic 
symptoms of migraine attack, such as nausea and photophobia, in addition to 
headache. Currently, seven triptans are available (sumatriptan, zolmitriptan, 
naratriptan, rizatriptan, eletriptan, almotriptan, and frovatriptan) with five 
different drug formulations (nasal spray, rectal, subcutaneous injection, oral 
tablets, and disintegrating tablets) (Tfelt-Hansen et al. 2000).  
Serotonin and its receptors are implicated in the pathophysiology of 
migraine. Several classes and subclasses of serotonin receptors have been 
identified. Two of these, 5-HT1B and 5-HT1D receptors, are the ones mainly 
believed to be involved in migraine. 5-HT1B receptors are expressed in the 
smooth muscle cells of intracranial blood vessels, and 5-HT1D receptors on 
the peripheral and central trigeminal nociceptive nerve terminals. Triptans 
have high affinities at 5-HT1 receptor subtypes, mainly the 5-HT1B and 5-
HT1D receptors. No profound differences exist between the individual triptans 
in affinities at the these receptors. Triptans also interact with 5-HT1A and 5-
HT1F receptors, and some have a minor affinity at the 5-HT7 receptor 
(Longmore et al. 1997, Schwedt 2007). 
Possible mechanisms of triptan action in migraine are as follows: 1) 
constriction of dilated cranial blood vessels via 5-HT1B receptors (Saxena et 
al. 1989, Humphrey et al. 1991), 2) inhibition of neurogenic inflammation 
around the blood vessels by reducing neuropeptide release and plasma 
protein extravasation (Moskowitz 1992), and 3) inhibition of nociceptive 
transmission centrally within the trigeminovascular system (Goadsby 1997). 
The importance of each of these mechanisms remains uncertain (Humphrey 
et al. 1994). Because of the constriction effect of triptans in the cranial 
vasculature, they should be taken in the headache phase of migraine attack, 
and not during aura or other premonitory symptoms.  
Although the pharmacological mechanism of individual triptans is similar, 
their pharmacokinetic properties can vary markedly. Especially the newer 
oral triptans have enhanced pharmacokinetic characteristics compared with 
the oral formulation of the first released triptan sumatriptan. These include 
more rapid attainment of therapeutic plasma levels, better oral bioavailability, 
and greater ability to cross the blood brain barrier. In contrast, these second-
generation triptans do not differ much from sumatriptan in their 
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pharmacodynamic properties, except for being more lipophilic, thus having a 
greater potential effect on the central part of the trigeminovascular system 
(Tfelt-Hansen et al. 2000). Pharmacokinetic parameters of triptans are listed 
in Table 4.
All triptans are effective in migraine therapy. Pain-relief response rates at two 
hours post-dose are generally between 50% and 80%, and are superior to 
placebo when used in adequate doses, although in comparative trials efficacy 
differences are often reported (Tfelt-Hansen et al. 2000, Ferrari et al. 2001b, 
Pascual et al. 2007). However, efficacy is not the only factor considered 
when choosing an appropriate treatment for a migraine patient. Factors such 
as rapidity of onset of action, headache recurrence rate, tolerability, route of 
administration, and adverse effects are also important. Furthermore, pain-
relief response to certain triptans can vary greatly between individuals. 
Adverse effects. Because of their receptor binding properties, all triptans 
have a similar adverse effect profile. They are generally well tolerated when 
used appropriately (Nappi et al. 2003). In the human coronary artery, 5-HT2
receptors are the most important receptors mediating vasoconstriction, but 
20-30% of the vasoconstriction is mediated by 5-HT1 receptors (Bax et al. 
1993). Therefore, 5-HT1B/1D agonists also constrict albeit to lesser extent, 
human coronary arteries and can in some cases induce cardiac ischemia. 
They are contraindicated in patients with cardiovascular diseases or marked 
cardiovascular risk factors, such as angina pectoris, arteriosclerosis, and 
uncontrolled hypertension. When used at therapeutic doses in patients 
without any coronary artery disorders, triptans are expected to have an 
insignificant effect on coronary arteries (Tfelt-Hansen et al. 2000). 
Considering the extensive use of especially sumatriptan in the past decade, 
the incidence of serious cardiac adverse events has been low (Welch et al. 
2000).
Chest symptoms (tightness, pressure, and pain in chest, neck, or throat) are 
typical adverse effects of triptans. They are observed in 15-40% of adult 
patients after administration of oral or subcutaneous sumatriptan (Dahlof et 
al. 1998). The pathophysiology of these chest symptoms remains uncertain, 
but they may be also caused by coronary vasoconstriction (Nappi et al. 2003). 
Chest symptoms are, however, more often observed in patients who generally 
have a lower incidence of cardiovascular risk factors. They are more often 
experienced by women than by men, by younger rather than older patients, 
and by those with a low rather than a high body mass index (Dahlof et al. 
1998).
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The mechanisms involved in pathogenesis of CNS adverse effects following 
the administration of triptans are also obscure. Since several of the central 
adverse effects (i.e. somnolence, dizziness, thinking difficulty) could overlap 
with symptoms typically occurring during a migraine attack, it is difficult to 
evaluate the actual incidence of CNS-associated adverse effects. Up to 
tenfold differences in the incidence of CNS adverse effects have been 
detected between individual triptans. The highest incidences have been 
reported for eletriptan, rizatriptan, and zolmitriptan, and the lowest 
incidences for almotriptan, sumatriptan, and naratriptan. The probable  
explanation for these differences is the combination of existing active 
metabolites and high lipophility of some triptans. Highly lipophilic triptans 
that penetrate the blood-brain barrier are associated with higher levels of 
CNS side-effects. Naratriptan (although highly lipophilic), almotriptan, and 
sumatriptan have no active metabolites and have a relatively low incidence of 
CNS effects, while frovatriptan, rizatriptan, zolmitriptan, and eletriptan have 
N-desmethyl active metabolites and a higher incidence of CNS adverse 
effects (Nappi et al. 2003, Dodick et al. 2004). 
9.1.4.1. Triptans in children and adolescents
There is a paucity of controlled data regarding the treatment of migraine with 
triptans in children and adolescents. 
Sumatriptan. The efficacy of oral sumatriptan was studied in a small 
placebo-controlled, cross-over trial of 23 children aged 8-16 years. At two 
hours, pain relief was reported by 30% of patients after sumatriptan (50 mg, 
or 100 mg in those over 12 years of age) and by 22% after placebo. The 
difference was not significant (Hämäläinen et al. 1997a). Trials of nasal 
sumatripan are reviewed in Section 10.1. 
Eletriptan. The efficacy and tolerability of eletriptan 40 mg was studied in 
274 adolescents aged 12-17 years in a placebo-controlled, double-blind, 
parallel-group trial. No difference was present in two-hour headache response 
for eletriptan versus placebo (57% vs. 57%), and no significant 
improvements were observed for any of the outcomes at one or two hours. 
Eletriptan 40 mg was well tolerated, and the profile of adverse effects was 
similar to that observed in adults (Winner et al. 2007). 
Review of the literature
38
Review of the literature
39
Zolmitriptan. Oral zolmitriptan (10, 5, or 2.5 mg) was compared with 
placebo in 850 adolescents aged 12-17 years in treatment of a single migraine 
attack. Headache relief rates at two hours were 54%, 53%, and 57% for 
zolmitriptan 10, 5, and 2.5 mg, respectively, and 58% for placebo (p=ns) 
(Rothner et al. 2006). Oral zolmitriptan 2.5 mg was also compared with 
placebo and ibuprofen (200 or 400 mg) in a three-way cross-over design for 
treatment of three consecutive migraine attacks in 32 children aged 6-18 
years. Pain relief rates at two hours were 28% for placebo, 62% for 
zolmitriptan, and 69% for ibuprofen (p<0.05) (Evers et al. 2006). Oral 
zolmitriptan was well tolerated in both of these trials. Zolmitriptan nasal 
spray 5 mg was studied a randomized, two-attack, cross-over trial with a 
novel ´placebo challenge´ design in 171 adolescents aged over 12 years. 
Attack was first treated with placebo nasal spray, and no additional 
medications were taken if a headache response to placebo spray was achieved 
at 15 minutes. If pain intensity remained moderate or severe, the patients 
treated the attack with zolmitriptan nasal spray or placebo according to a 
randomized crossover schedule. The primary efficacy endpoint, headache 
relief at one hour, was achieved by 58.1% of patients after zolmitriptan and 
by 43.3% after placebo (p<0.05). Treatment with zolmitriptan nasal spray 
was well tolerated (Lewis et al. 2007).
Trials of rizatriptan are reviewed in Section 10.2. No placebo-controlled trials 
of efficacy of naratriptan, almotriptan, or frovatriptan have been published in 
children and adolescents. 
9.2. Prophylactic treatment 
Prophylactic treatment should be considered when migraine attacks persist
two to three times per month regardless of lifestyle changes and other 
nonpharmacological interventions, and these attacks result in significant 
disability to the child life at school or in social relationships. If started, 
preventive treatment should be used at least 6-12 weeks before it can be 
considered ineffective. Slowly titrating the dose to an effective level is 
recommended. When prophylactic treatment is effective, it should be 
continued at least six months (Winner 2008).  
Numerous agents have been used for migraine prophylaxis in children, but 
only a few controlled clinical trials are available. Clinical trials have not 
shown that one drug is clearly superior to others when also potential adverse 
effects are taken into consideration (Pakalnis 2007).  
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The American Academy of Neurology Practice Parameters for physicians 
stated that the best research evidence has emerged for the calcium channel 
blocker flunarizine, which is "probably effective", and can be considered for 
prophylactic purposes for childhood migraine (Lewis et al. 2004a). However, 
this evidence is questionable, as none of the studies that showed the efficacy 
of flunarizine adequately considered its long half-life (almost one month) in 
their study protocols (Hoppu et al. 1995). Flunarizine can also have marked 
adverse effects, e.g. sedation, weight gain, and extrapyramidal effects. 
Insufficient evidence exists for other drugs to make any recommendations for 
their prophylactic use in childhood migraine (Lewis et al. 2004a). However, 
increasing data are emerging for efficacy of the antiepileptic drug topiramate 
in migraine prophylaxis in children. Several small studies over the last years 
have reported a reduction rate superior to placebo for migraine frequency. 
Adverse effects are notable and include weight loss, impaired concentration, 
emotional instability, paresthesias, anorexia, sedation, and abdominal pain. 
These must be strictly monitored when topiramate is used (Eiland et al. 
2007).
Other drugs used for migraine prophylaxis in children, based on varying 
amounts of research data, include the antihistamines cyproheptadine and 
pizotifen (also have antidepressive properties), the antidepressants 
amitriptyline and trazodone, the antihypertensive agents propranolol (and 
other ?-adrenoceptor blockers), nimodipine, and clonidine, the antiepileptic 
drugs divalproex sodium and gabapentin, the NSAID naproxen, and the 
natural supplemental agents magnesium oxide, riboflavin, and coenzyme Q10 
(Lewis et al. 2004b, Eiland et al. 2007, Pakalnis 2007, Winner 2008).     
In Finland, propranolol is probably the most commonly used prophylactic 
agent in children. It is also the first-line therapy for migraine prophylaxis 
recommended by the Finnish Current Care Guideline of Childhood Headache 
(Suomen Lastenneurologinen Yhdistys ry:n asettama työryhmä 2003), 
although research for its efficacy is controversial, and superiority to placebo 
remains unproven (Eiland et al. 2007). It is thought to improve migraines by 
modulating adenoreceptors or inhibiting serotonin receptors. The 
recommended dose for children aged seven years and older is 0.5-2 
mg/kg/day (max 160 mg/day). Propranolol can decrease blood pressure, 
reduce heart rate, induce hypoglycemia, and exacerbate asthma symptoms 
(Suomen Lastenneurologinen Yhdistys ry:n asettama työryhmä 2003). 
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9.3. Nonpharmacological treatment of migraine in children 
Avoidance of attacks is the simplest approach to nonpharmacological 
treatment of migraine. As a child with migraine may have a genetic 
predisposition for this condition, it is usually not possible to prevent attacks 
completely by avoiding attack triggers. Potential triggers can best be 
identified by keeping a headache calendar or diary regularly. Lifestyle 
adjustments are often effective in diminishing attack frequency.  
9.3.1. Avoidance of trigger factors
Trigger factors were identified by 18% of children aged 3-7 years with 
migraine and by 44% of children aged 8-11 years. Dietary factors were 
reported by 12% of the younger age group and 8% of the older age group. 
Stress was a precipitant in 6% of the younger group and 14% of the older 
one. In children over eight years of age, tiredness (8%), exercise (3%), noise 
(3%), glaring light (3%), missing a meal (3%), and studying (3%) were 
identified as migraine triggers (Mortimer et al. 1992a). Adolescents are 
probably more capable of identifying attack triggers than younger children. 
In those aged 11-15 years, the most frequent triggering factor for migraine 
headache was bad sleep (32%), followed by emotional distress (28%) (Bruni 
et al. 2007). Of children aged 6-16 years, 41% cited stress as a trigger for 
migraine headache. Other triggers were bright lights (28%), overtiredness 
(26%), exercise (23%), missing meals (10%), and certain foods (8%). No 
trigger was identified by 26% of children (Cooper et al. 1987).
Children with migraine should maintain a regular daily rhythm, with regular 
meals (especially breakfast) and sufficient physical exercise and sleep 
(Hämäläinen 2006). Before considering the elimination of certain foods from 
the diet, the headache trigger should be identified certainly from carefully 
filled out headache diaries. The elimination of all possible dietary triggers of 
migraine is not recommended for safety and nutritional reasons. A well-
balanced diet is important, and skipping meals or fasting should be avoided 
(Millichap et al. 2003). The duration and frequency of migraine attacks can 
also be reduced by improving sleeping habits with sleep hygiene guidance 
(Bruni et al. 1999). 
9.3.2. Behavioral treatments 
Increasing evidence suggests that behavioral interventions, particularly 
biofeedback and relaxation therapy, might be more effective than commonly 
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used prophylactic drugs in treating childhood migraine (Hermann et al. 1995, 
Baumann 2002). The physiological basis for their effectiveness is unclear, 
but data from one trial suggest that levels of plasma ?-endorphin can be 
altered by relaxation and biofeedback therapies (Helm-Hylkema et al. 1990). 
Acupuncture. There is some evidence that acupuncture is effective in 
relieving symptoms in childhood migraine. Frequency and intensity of 
migraine were reduced in children with migraine who received ten true 
acupuncture treatments compared with those who received placebo 
acupuncture (needles in horny layer of epidermis) (Pintov et al. 1997).  
Stress management. Stress management teaches patients to deal with the 
affective component of headache, in contrast to relaxation and biofeedback 
therapies, which focus on self-regulation of physiological responses 
(Baumann 2002). A widely used technique in stress management is to have a 
child keep a diary of headaches, stressors, and headache-associated activities 
to identify behaviors that seem to be related to headaches and then to alter 
this adverse behavior (McGrath et al. 1995). ´Confident reassurance´, i.e. 
reassuring the child and parents that no serious illness is causing the child´s 
headaches, can lead to headache improvement (McGrath et al. 1995).   
Relaxation therapies. Relaxation therapies use such techniques as 
progressive relaxation, self-hypnosis, and guided imagery without employing 
a feedback apparatus. Several studies have found relaxation therapies to be as 
effective, or even more effective, in reducing the frequency of migraine 
headaches than modest doses of a ?-blockade medication (Baumann 2002).  
Biofeedback therapies. Biofeedback therapies use an apparatus to 
demonstrate a physiological effect. Most commonly in children, thermal 
biofeedback is used: the child is taught to raise the temperature of a body 
part, typically a finger, with the temperature expressed by a visual display or 
an auditory signal (Baumann 2002). Several studies have shown that these 
techniques can be easily taught to children and that their use is associated 
with fewer and briefer migraine attacks (Hermann et al. 1995, Powers et al. 
2001, Baumann 2002).
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10. Characteristics of compounds studied here  
Migraine attacks in children and adolescents are of shorter duration than in 
adults, so the ideal drug for treatment would be a formulation that has a rapid 
onset of action. It should also be easy and painless to administer, as injection 
is not favored by most children. When starting this thesis, hardly any 
information existed on the efficacy and safety of triptans in children. No 
triptan was licensed for use in children, and oral sumatriptan had failed to 
prove efficiency in a placebo-controlled trial (Hämäläinen et al. 1997a). As 
one-third of children with migraine seem to need more efficacious treatments 
than NSAIDs (Hämäläinen et al. 1997c), there was an absolute need for a 
better drug for acute treatment of childhood migraine. Intranasal sumatriptan 
and oral rizatriptan were selected as study drugs. Intranasal sumatriptan is 
rapid in action, and absorption begins immediately after dosing. It can also be 
administered if nausea or vomiting impede oral administration. Rizatriptan is 
the most rapidly absorbed oral triptan. It reaches Cmax quickly; this is 
favorable when treating childhood migraine, which has a shorter attack 
duration compared with adult migraine (Tfelt-Hansen et al. 2000).
10.1. Intranasal sumatriptan
Pharmacokinetics. Sumatriptan is a selective agonist of 5-HT1B/1D receptor
subtypes. After an insufflation, a fraction of the dose is believed to be 
absorbed initially through the nasal mucosa, while the remainder is 
swallowed and absorbed through the gastrointestinal tract. This produces 
multiple peak plasma sumatriptan concentrations (Moore et al. 1997). 
Interindividual differences exist in absorption of the swallowed portion of the 
intranasal dose, as the gastric emptying and the small bowel transit rate can 
vary greatly. Sumatriptan 5, 10, or 20 mg given as a single nasal insufflation 
in one nostril to adults produced mean Cmax values of 4.7 to 14.4 μg/L in 
median times of 1-1.5 hours. After a 20-mg intranasal dose, 68-84% of Cmax 
is achieved already in 15 minutes, whereas comparable serum concentrations 
after an oral dose require 30-60 minutes (Fowler et al. 1991). Cmax and AUC 
values increase in a dose-proportional manner after the single dose of 5, 10, 
and 20 mg (Salonen et al. 1994).  
Pharmacokinetic parameters other than those related to absorption are similar 
after intranasal sumatriptan compared with other administration formulations. 
Sumatriptan has a large volume of distribution ranging from 170 to 203 L 
after a single 6-mg subcutaneous dose. Plasma protein binding is low (14-
21%) over a wide range of drug concentrations. Distribution of sumatriptan 
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in the CNS is poor, and penetration across the blood-brain barrier is slow. 
Sumatriptan is extensively metabolized in the liver, and possibly in the 
gastrointestinal tract, by monoamine oxidase A (MAO-A) to a 
pharmacologically inactive indoleacetic acid analog, which is mainly 
excreted as a free acid and as a glucuronide conjugate in urine. A small 
proportion of the metabolite is excreted in feces. The T1/2 of the therapeutic 
dose is about 2 hours, irrespective of the administration route (Fowler et al. 
1991, Perry et al. 1998).
Pharmacokinetics in children. The pharmacokinetics of intranasal 
sumatriptan have been studied in children aged 6-11 years (Christensen et al. 
2004) and in adolescents aged 12-17 years (Christensen et al. 2003). The 
pharmacokinetic parameters after sumatriptan 20 mg in adolescents were 
similar to those reported for adults, suggesting that adolescents could receive 
a similar dose to adults. In younger children, sumatriptan dosage was based 
on age and weight. Children aged 6-8 years and weighing under 25 kg 
received a dose of 5 mg, those aged 9-11 years and weighing under 40 kg a 
dose of 10 mg, and those aged 9-11 years and weighing over 40 kg a dose of 
20 mg. This dosing scheme resulted in Cmax and AUC comparable with 
those observed in adolescents and adults after a dose of 20 mg. Other 
pharmacokinetic parameters were also similar to those in adolescents and 
adults.
Efficacy. All published controlled trials in adults have confirmed the 
superiority of intranasal sumatriptan to placebo in relieving migraine 
headache and other migraine-associated symptoms. Headache relief at two 
hours was experienced by 55-78% of patients after sumatriptan 20 mg 
compared with 29-42% of patients after placebo (Perry et al. 1998, Dahlof 
1999). A complete pain-free response seems to be dose-dependent, being 26-
42% after sumatriptan 20 mg at two hours and 4-20% after placebo (Dahlof 
1999). Intranasal sumatriptan has a rapid onset of action, with some patients 
experiencing headache relief in 15 minutes, which is less than that reported 
for the oral formulation. Headache relief 30 minutes after intranasal treatment 
was achieved in 38% of 120 patients, but in only 2% of the 47 patients 
treated with oral sumatriptan (Rapoport et al. 2004).
Efficacy in children. Efficacy of intranasal sumatriptan in adolescents has 
been evaluated in a few placebo-controlled studies in recent years. A parallel-
group single-attack study in 510 adolescents aged 12-17 years with randomly 
administered sumatriptan 5, 10, or 20 mg reported that at one hour post-dose 
56% of patients after sumatriptan 10 mg and 56% after sumatriptan 20 mg 
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experienced pain relief, while this was true for only 41% of patients after 
placebo (p<0.05). At two hours, significantly more patients after sumatriptan 
5 mg (66%) reported headache relief compared with placebo (53%; p<0.05). 
Significance was also approached for sumatriptan 20 mg (63%) compared 
with placebo (53%; p= 0.059). A significantly greater proportion of patients 
(36%) reported being completely pain-free after sumatriptan 20 mg compared 
with placebo (25%; p<0.05). Headache recurrence after initial headache relief 
within 24 hours was reported by 18% and 16% of patients after sumatriptan 5 
and 20 mg, respectively. No significant difference existed between these 
recurrence rates and the rate after placebo (20%) (Winner et al. 2000).  
A second trial by the same authors investigated the efficacy of intranasal 
sumatriptan 5 and 20 mg compared with placebo in a parallel-design single-
attack study in 738 adolescents aged 12-17 years. Sumatriptan 20 mg 
provided significantly greater headache relief than placebo at 30 minutes 
(42% vs. 33%; p=0.046) and at two hours (68% vs. 58%; p=0.025), but 
significance was not reached at one hour postdose (61% vs. 52%; p=0.087). 
Pain-free response was reported more often after sumatriptan 20 mg (44%) 
than after placebo (30%; p<0.001). Response rates after sumatriptan 5 mg 
were in general slightly higher than after placebo, but did not reach statistical 
significance at any time-point. Headache recurrence after initial relief was 
reported by 24% of patients after sumatriptan 20 mg and by 31% after 
placebo within 24 hours after treatment (Winner et al. 2006). 
Only one placebo-controlled trial of efficacy of intranasal sumatriptan in 
children under 12 years of age has been published. This small two-way cross-
over trial of 14 children aged 6-10 years reported response rates of 86% after 
sumatriptan 20 mg and 43% after placebo at two hours postdose (p=0.031). 
Complete pain-free response at two hours was achieved by 64% after 
sumatriptan and by 14% after placebo (p=0.016). Headache recurrence was 
not observed (Ueberall et al. 1999).
Tolerability. Intranasal sumatriptan is generally well tolerated, and adverse 
effects are usually mild and transient. However, all adverse effects generally 
associated with triptan treatment are possible (described in Section 9.1.4.), 
and intranasal sumatriptan is contraindicated in migraine patients with any 
cardiovascular risk factors (Perry et al. 1998). There is no evidence of long-
term nasal irritation, blockade, or olfactory dysfunction after single or 
multiple doses of intranasal sumatriptan. The most commonly reported 
adverse effect, which is not dose-related, is the bitter taste of the drug (Moore 
et al. 1997).
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Tolerability in children. The taste disturbance has been the most common 
drug-related adverse effect also in children and adolescents in all trials. It is 
the only adverse effect that is significantly more often reported after 
sumatriptan than after placebo. Other drug-related adverse effects include 
nausea, vomiting, dizziness, and nasal/throat/tonsil discomfort or burning 
sensation (Ueberall et al. 1999, Winner et al. 2000,  2006).  
The one-year tolerability of intranasal sumatriptan was studied in 437 
patients aged 12-17 years at doses of 5, 10, and 20 mg with a total of 3675 
drug exposures. Drug-related adverse events were reported in 33% of the 
attacks after sumatriptan 10 mg, and in 31% of the attacks after sumatriptan 
20 mg. Adverse effects did not increase with a second dose or over time. 
When taste disturbance was excluded from the tabulations, the incidence of 
drug-related adverse effects declined to 7% with both the 10- and 20-mg 
doses (Rothner et al. 2000). Another one-year tolerability study with 484 
adolescents aged 12-17 years with 4676 drug exposures with one, two, or 
three doses of sumatriptan 20 mg reported drug-related adverse effects in 
19% of attacks. When taste disturbance was excluded from the tabulations, 
the appearance of adverse effects declined to 4% (Natarajan et al. 2004). 
10.2. Rizatriptan 
Pharmacokinetics. Rizatriptan is an orally active serotonin 5-HT1 receptor 
agonist that binds potentially and selectively to 5-HT1B/1D receptor subtypes. 
It is available as an oral tablet and as an orally disintegrating tablet (wafer). 
The minimum effective dose for rizatriptan in adults is 5 mg, with the 
optimum dose being 10 mg (Dahlof et al. 1999). Oral rizatriptan is readily 
absorbed from the gastrointestinal tract (~ 90%), with overall bioavailability 
being about 45% (Vyas et al. 2000, Goldberg et al. 2001). In adults, Cmax 
and AUC of rizatriptan increases in a dose-proportional manner after single-
dose rizatriptan 5 to 60 mg (7.8-90 μg/L and 17.4-394.5 μg•h/L, 
respectively). The Tmax after a single dose of rizatriptan 2.5-60 mg ranges 
from 0.7 to 2.1 hours. Rizatriptan (5-60 mg) has a faster rate of absorption 
than oral sumatriptan 100 mg (median 1.3 vs. 2.5 hours) (Sciberras et al. 
1997). The absorption seems to be independent of gastric stasis, as both 
Cmax and AUC are similar during and between migraine attacks (Cutler et 
al. 1999). Rizatriptan is minimally bound to plasma proteins (14%) 
(Wellington et al. 2002).  
Rizatriptan is extensively metabolized by MAO-A, primarily to inactive 
metabolites, of which most are excreted in urine and small amounts in faeces. 
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Rizatriptan has one active minor metabolite, N-monodesmethylrizatriptan, 
which is twice as potent a 5-HT1B/1D agonist as rizatriptan (Goldberg et al. 
2000). The mean T1/2 of oral rizatriptan 2.5-60 mg is between 1.7 and 2.6 
hours (Wellington et al. 2002).  The AUC and Cmax are significantly 
increased with coadministration of rizatriptan with propranolol (but not 
metoprolol); the dose of rizatriptan should be reduced to 5 mg if administered 
to a patient also receiving propranolol (Goldberg et al. 2001).
Pharmacokinetics in children. The pharmacokinetics of rizatriptan has been 
studied in 12 adolescents with migraine. Rizatriptan was well tolerated, and 
the AUC and Cmax after single-dose administration of 10 mg were similar to 
values observed in adults (Winner et al. 1998). 
Efficacy. Superiority of rizatriptan over placebo in relieving migraine 
headache and other migraine-associated symptoms has been found in all 
published controlled trials in adults (Wellington et al. 2002). A meta-
analysis, including seven randomized studies with rizatriptan 10 mg and six 
studies with rizatriptan 5 mg, reported headache relief response rates of 45% 
and 38%, respectively (placebo 25%), at one hour, and 71% and 64% 
(placebo 38%) at two hours (Ferrari et al. 2001a). At two hours, 41% of the 
patients after rizatriptan 10 mg and 32% after 5 mg were completely pain-
free compared with 10% after placebo. Response rates of similar magnitude 
have been reported in all published clinical trials (Dooley et al. 1999, Tfelt-
Hansen et al. 2000, Jhee et al. 2001, Wellington et al. 2002). Headache 
recurrence rates are relatively high, ranging from 29% to 47% for rizatriptan 
10 mg (Jhee et al. 2001).    
Efficacy in children. Efficacy of rizatriptan 5 mg has been investigated in
two placebo-controlled parallel-group single-attack trials in adolescents aged 
12-17 years. In the first study, headache relief at two hours was reported by 
66% of the 149 patients after rizatriptan 5 mg and by 56% of the 142 patients 
after placebo (p=ns). Of these patients, 32% after rizatriptan and 28% after 
placebo were completely pain-free. Headache recurrence was experienced by 
14% of those who initially responded to treatment at two hours (Winner et al. 
2002). Post hoc analysis showed a significant benefit of rizatriptan over 
placebo when migraine attacks were treated on weekends (headache relief at 
two hours 65% vs. 36%, p=0.046). In the second trial, children were 
instructed to treat an attack on non-school days. Pain relief at two hours was 
reported by 68.2% after rizatriptan 5 mg and by 68.8% after placebo. Only 
30% of subjects treated their attacks on the weekend as instructed; in this 
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subgroup of patients, rizatriptan was superior to placebo in relieving 
headache at two hours (75% vs. 58%, p=0.022) (Visser et al. 2004).
Tolerability. Rizatriptan is well tolerated and adverse events are usually mild 
and transient. The incidence of adverse effects was similar after single- and 
multiple-dose administration (up to 3 doses in 24 hours) and appeared to be 
dose-related. The most common adverse effect (incidence > 5%) associated 
with rizatriptan 5 or 10 mg are CNS- or gastrointestinal-related, including 
fatigue, dizziness, somnolence, and nausea (Kramer et al. 1998). Chest pain 
is reported by 1-3% of patients after rizatriptan 5 or 10 mg (Goldstein et al. 
1998). All adverse effects generally associated with triptan treatment are 
possible (described in Section 9.1.4.). The overall rate of drug-related adverse 
effects after a single dose was 22% after rizatriptan 5 mg, 31% after 
rizatriptan 10 mg, and 16% after placebo.. Rizatriptan, like other triptans, is 
contraindicated in migraine patients with any cardiovascular risk factors 
(Wellington et al. 2002).  
Tolerability in children. In two placebo-controlled trials and two open-label 
multiple attacks studies in adolescents aged 12-17 years, rizatriptan 5 mg  
was generally well tolerated (Winner et al. 2002, Visser et al. 2004). In the 
first placebo-controlled trial, 34% of patients after rizatriptan 5 mg and 35% 
after placebo reported an adverse effect. The most common adverse effects 
were asthenia, dizziness, dry mouth, nausea, and somnolence. Nausea and 
somnolence were reported more often after placebo than after rizatriptan. 
There were no serious drug-related adverse effects (Winner et al. 2002). 
Results were similar in the second controlled trial. Moreover, in open-label 
multiple-attack studies (686 patients treating 8734 attacks), drug-related 
adverse effects were reported by 30% after rizatriptan 5 mg, 30% after 
rizatriptan 5 mg wafer, and 25% after standard care, the  most common 
adverse events being dizziness, somnolence, and nausea (Visser et al. 2004).
11. Placebo effect in the treatment of migraine
Placebo-controlled clinical trials are the gold standard to show the efficacy of 
drugs. In these, the response to the studied drug should be statistically 
superior to the response to placebo. This principle is in concordance with IHS 
guidelines regarding controlled trials of acute migraine medications 
(International Headache Society Clinical Trials Subcommittee 2000).  
Placebos have been reported to improve subjective and objective outcomes in 
up to 30-40% of adult patients with a wide range of clinical conditions, such 
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as pain, asthma, high blood pressure, and even myocardial infarction 
(Beecher 1955, Brown 1998). Patients with migraine can also experience 
considerable headache relief after placebo. In a meta-analysis of placebo 
response in 98 trials studying the efficacy of acute migraine treatments in 
adults using a placebo as a control, headache relief at two hours after placebo 
was reported by 28.6% of patients, and 8.8% were completely pain-free 
(Macedo et al. 2006). Another meta-analysis of placebo response in 31 trials 
comparing the efficacy of different oral triptans and placebo in adults 
reported a similar response rate of 28.90% (ranging from 17% to 50%) at two 
hours after placebo, and a pain-free response rate of 6.08% (Loder et al. 
2005). In a trial where patients treated moderate or severe migraine attack 
only with an oral placebo, 37% of patients experienced headache 
improvement at two hours and 48% within four hours (Jhee et al. 1998). 
In clinical trials in children and adolescents with migraine, the placebo 
responses have generally been much higher than the responses reported in 
adults. Because of this, a statistical difference between an active treatment 
and placebo has been challenging to detect, although the responses to active 
treatments have generally been of a similar magnitude as seen in adults 
(Lewis et al. 2005). A recent review has evaluated placebo responses in 13 
controlled trials of acute migraine treatment in children and adolescents 
(Fernandes et al. 2008). The placebo responses for pain relief and pain-free 
rates at two hours were 46% (range 38-53%) and 21% (range 17-26%), 
respectively. Studies conducted in North American research centers 
demonstrated higher placebo responses, as did trials that used four-point vs. 
five-point pain scales. A five-point pain scale might be more sensitive in 
distinguishing the level of pain in children. Trials with parallel design 
compared with cross-over design reported higher placebo response rates; the 
same has also been seen in adult studies (Macedo et al. 2006). One factor 
probably interacting with the higher placebo response in children is the 
shorter duration of attacks compared with adults, and thus, a more rapid 
spontaneous recovery rate.
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AIMS OF THE STUDY
Migraine attacks in children and adolescents are painful and disabling, and 
thus, an effective treatment is needed. A new class of migraine drugs, 
triptans, were introduced at the beginning of the 1990s and have since been 
shown to be very effective in the treatment of migraine attacks in adults. 
Although these drugs are widely used in adults, the treatment of migraine 
attacks of children and adolescents is still mainly based on paracetamol and 
ibuprofen or other NSAIDs. These are effective for many patients, but 30% 
need more powerful treatments. When these studies commenced, hardly any 
information existed on the efficacy and safety of triptans in children and 
adolescents. The aim here was to gain information on the efficacy of triptans 
in children and adolescents as well as to offer a more efficient migraine 
treatment to this group of patients.  
Sleep has a multifold impact on migraine. It is a part of the natural healing 
process of a migraine attack, and it is the most common and preferred 
nonpharmacological treatment of a migraine attack in children. It has 
relevance also in the assessment of drug effects in clinical trials of migraine 
medicines in children. How a sleeping child should be classified in drug trials 
is under continual debate. Despite the clinical relevance and common 
manifestation of sleep in the context of migraine, very little research data on 
its true frequency exist thus far. An objective here was to gain more 
information on sleep during  migraine attacks.    
Specific aims of the studies were as follows: 
1. To investigate the frequency of falling asleep and factors influencing this 
during migraine attacks in children and adolescents aged 4-17 years (Study 
I).
2. To clarify how the results of a sleeping child should be analyzed in clinical 
trials with children and adolescents (Studies I-III). 
3. To compare the efficacy of intranasally administered sumatriptan and 
placebo in children and adolescents aged 8-17 years with migraine attacks 
resistant to NSAID and paracetamol treatments (Study II). 
4. To compare the efficacy of oral rizatriptan and placebo in children and 
adolescents aged 6-17 years with migraine attacks resistant to NSAID and 
paracetamol treatments (Study III).  
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5. To evaluate the consistency of response between first and second attacks 
treated with rizatriptan (Study III). 
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MATERIALS AND METHODS
1. Ethical issues 
The study protocols were approved by the Ethics Committees of the 
participating hospitals: the Hospital for Children and Adolescents in Helsinki 
University Central Hospital (Studies II and III), Jorvi Hospital in Espoo 
(Studies II and III), and Oulu University Central Hospital (Study II). Study I 
was a prospective study that did not need a new Ethics Committee approval, 
but the studies during which the material was collected were approved by the 
Ethics Committees of the Hospital for Children and Adolescents, Jorvi 
Hospital, and Aurora Hospital in Helsinki. The study protocols of the drug 
trials (Studies II and III) were approved by The Finnish National Agency for 
Medicines. The studies were conducted in accordance with the Declaration of 
Helsinki. Written informed consent from parents of all participating children 
was obtained before enrolment in Studies II and III. Written assent was 
obtained from children 12 years of age or older; younger children gave their 
assent orally.
2. Patient recruitment and follow-up 
Study I. The study material, i.e. headache diaries, was collected during the 
study of optimal drug treatment of childhood migraine performed during 
1992-1995 by Dr. Mirja Hämäläinen (Hämäläinen 1997). Headache diaries 
included here were not included in the analyses of Dr. Hämäläinen´s thesis. 
All participating children were outpatients of the Hospital for Children and 
Adolescents, Jorvi Hospital, or Aurora Hospital. Migraine was diagnosed 
according to IHS criteria for migraine with or without aura (Headache 
Classification Committee of the International Headache Society 1988).
Study II. Patients were recruited at the headache outpatient clinic set up for 
the study and run by the author on a weekly basis at the Division of Child 
Neurology in the Hospital for Children and Adolescents and at the Pediatric 
Division of Jorvi Hospital. Furthermore, Dr. Mirja Hämäläinen at the 
Hospital for Children and Adolescents and Dr. Heikki Rantala at Oulu 
University Central Hospital recruited and followed up some of the patients. 
Patients were recruited between September 1999 and December 2000, and 
the trial was completed in March 2001. 
Study III. Patients were recruited at the headache outpatient clinic, which 
was set up for the study and run by the author at the Division of Child 
Materials and methods 
53
Neurology in the Hospital for Children and Adolescents and at the Pediatric 
Division of Jorvi Hospital. Furthermore, Dr. Mirja Hämäläinen at the 
Hospital for Children and Adolescents recruited and followed up some of the 
patients. Patients were recruited between January 2001 and November 2003, 
and the trial was completed in February 2004.
Inclusion criteria in Studies II and III. Any child aged 8-17 years (Study 
II) or 6-17 years (Study III) with a body weight of 20 kg or more, referred to 
a participating hospital or already being treated for migraine at the hospital 
was eligible to participate in Studies II and III. Migraine was diagnosed 
according to IHS criteria for migraine with or without aura (Headache 
Classification Committee of the International Headache Society 1988). 
Children needed to have at least two migraine attacks per month lasting four 
hours or more, and to have previously unsatisfactory migraine therapy with 
paracetamol or NSAIDs. They had to be capable of using a headache diary 
and a face scale properly.
Exclusion criteria in Studies II and III. Exclusion criteria were history of 
renal, hepatic, or cardiovascular disease or any other disease necessitating 
continuous daily oral drug therapy. Strong heredity of coronary artery disease 
in the family, assessed as clinical symptoms in males under 40 years of age 
or in females under 50 years of age, prevented participation. None of the 
children received prophylactic drug therapy for migraine at the time of the 
study.
Follow-up in Studies II and III. Before entering the trial, patients were 
examined in a migraine-free state with complete physical and neurological 
examinations, a blood sample (complete blood count, sodium, potassium, 
calcium, inorganic phosphorus, creatinine, alanine aminotransferase, 
aspartate aminotransferase, alkaline phosphatase, glucose), and a urine 
sample (appearance, color, pH, gravity, protein, glucose, ketones) to exclude 
other etiologies of headache. An EEG or neuroimaging was performed if 
needed. The pubertal stage of adolescents was assessed by the Tanner scale 
(Tanner 1962). Patients went through a run-in period (range 0-3.9 months in 
Study II, and 0-13.7 months in Study III) prior to entering the study. During 
this period the diagnosis, fulfilment of inclusion criteria, and ability to use the 
headache diary and pain scale were confirmed. Physical and neurological 
examinations were performed before and after the run-in period, and after the 
study drugs were administered. Many of the patients also had additional 
visits.
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3. Patient characteristics 
Study I. This study included 133 patients with 999 registered migraine 
attacks. The mean age of the children was 10.8 (range 4.6 to 16.9) years, and 
70 (52.6%) were boys.
Study II. Altogether 129 patients were recruited to the study, and 94 of these 
returned their headache diaries. The mean age of these 94 children was 12.4 
(SD 2.4, range 8.1-17.5) years, and 51 (54.2%) were boys. Migraine with 
aura was experienced by 30.9% (n=29/94) of the children. They had a median 
migraine history of 3.8 (range 0.5-13.5) years, a median attack duration of 8-
12 hours, and a median attack frequency of 1 or 2 attacks per week. Patients´ 
migraine characteristics during the first visit are listed in Table 5. 
Study III. Altogether 147 patients were recruited to the study, and 116 of 
these returned their headache diaries. The mean age of these 116 children was 
12.0 (SD 2.4, range 6.1-16.1) years, and 63 (54.3%) were girls. Migraine 
with aura was experienced by 28.5% (n=33/116). They had a median 
migraine history of 4.0 (range 0.5-12.0) years, a median attack duration of 4-
8 hours, and a median attack frequency of 3 or 4 attacks per month. Patients´ 
migraine characteristics during the first visit are listed in Table 5. 
4. Study structure
Study I. A prospective study where patients recorded their migraine attacks 
in a headache diary using either a five-face pain scale, or a 100-mm Visual 
Analog Scale (VAS) chosen according to the child’s own preference (Figure 
2) (Appendix A). A close correlation between the five-face scale and the 
continuous visual scale has been demonstrated earlier (Maunuksela et al. 
1987). To combine information from the two scales, the VAS data were 
transformed as follows: 0 to ?12 = grade 1, 13 to ?37 = grade 2, 38 to ?62 = 
grade 3,  63 to ?87 = grade 4, and 88 to ?100 = grade 5. Headache intensity 
was reported at the beginning of the attack, 30 minutes later, and then hourly 
for a maximum of five hours. Further remarks were made about falling 
asleep, nausea, vomiting, and other accompanying symptoms. For analyses, 
attacks were classified according to the mode of ending: 1) attacks that ended 
in falling asleep (within the first 0.5 hour, between 0.5 and 1 hour, between 1 
and 2h or 2 hours or more from onset of headache); 2) attacks that ended 
without sleep (duration less than 2 hours, from 2 to 4 hours, or more than 4 
hours); and 3) attacks in which the resolution of symptoms was not registered 
(duration less than 5 hours or more than 5 hours). For evaluation purposes, 
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patients were grouped according to their age as follows: patients younger 
than 8 years, those between 8 and 12 years, and those older than 12 years. 
The effect of the drugs administered was not analyzed, as the aim of the 
study was to evaluate what happens in a real clinical situation at home.
Study II. The trial was a double-blind, randomized, placebo-controlled, two-
way cross-over efficacy study of sumatriptan nasal spray and placebo. Each 
child treated two migraine attacks at home with study drugs of identical 
appearance, one being sumatriptan and the other a placebo. Both treatments 
were given to a child at the visit after the run-in period. They were clearly 
numbered one (the first treatment) and two (the second treatment) to ensure 
usage in the proper sequence. The sumatriptan dose was 10 mg for children 
with a body weight of 20 to 39 kg and 20 mg for those with a body weight of 
40 kg or more. Children were instructed to take a single nasal insufflation at 
the onset of a migraine attack if headache severity was classified as three or 
more on a five-face pain intensity scale (Figure 2). Rescue medication, 
NSAIDs or acetaminophen, was allowed at any point if needed, but waiting 
two hours after taking the study drug was recommended. Headache 
recurrence after the initial response to the study drug was treated with 
NSAIDs or acetaminophen, if medication was required. 
Study III. The trial was a double-blind, randomized, placebo-controlled, 
three-way cross-over efficacy study of oral rizatriptan and placebo. Each 
child treated three migraine attacks at home with study drugs packed in 
capsules of identical appearance, two of them being rizatriptan and one a 
placebo. Rizatriptan was given twice to test the stability of the treatment 
effect in two consecutive migraine attacks. All three treatments were given to 
a child at the visit after the run-in period. They were clearly numbered one 
(the first treatment), two (the second treatment), and three (the third 
treatment) to ensure usage in the proper sequence. The rizatriptan dose was 5 
mg for children with a body weight of 20-39 kg and 10 mg for those with a 
body weight of 40 kg or more. Children were instructed to take a single 
capsule at the onset of a migraine attack if headache severity was classified as 
three or more on a five-face pain intensity scale (Figure 2). Rescue 
medication, NSAIDs or acetaminophen, was allowed at any point if needed, 
but waiting two hours after taking the study drug was recommended. 
Headache recurrence after the initial response to the study drug was treated 
with NSAIDs or acetaminophen, if medication was required. 
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Table 5. Patients´ migraine characteristics during the first visit in Studies II and III.
Characteristic Study II (n=94)(%) Study III (n=116)(%) 
Headache intensity 
5 70 (74) 87 (75) 
4 23 (25) 27 (23) 
3 1 (1) 2 (2) 
Attack frequency per month 
  <1 1 (1) 0
1-2 29 (31) 33 (28) 
  3-4 16 (17) 47 (41) 
  >4 48 (51) 36 (31) 
Attack duration (hours) 
  2-4 1 (1) 0
  4-8 44 (47) 68 (59) 
8-12 26 (28) 32 (28) 
12-24 18 (19) 10 (9) 
over 24 5 (5) 6 (5) 
Aura 29 (31) 33 (28) 
Photophobia 90 (96) 112 (97) 
Phonophobia 69 (73) 86 (74) 
Bedridden 93 (99) 116 (100) 
Unilateral headache 54 (57) 82 (71) 
Throbbing headache 61 (65) 109 (94) 
Nausea or vomiting 90 (96) 110 (95) 
5. Dose selection (Studies II and III) 
The selection of dose was based on the mg/body surface area (BSA) observed 
in adults by using the equation: Dosechild = Doseadult x (BSAchild / 1.73m2). The 
BSA of the child was calculated by the Haycock formula (Haycock et al. 
1978): BSA (m2)= 0.024265 x  Height (cm)0.3964 x Weight (kg)0.5378. Finnish 
height and weight curves (with plus/minus 2SD) for the appropriate ages 
were utilized when BSA was changed to kilograms. Sumatriptan 10 mg and 
rizatriptan 5 mg were selected for children weighing less than 40 kg (but over 
20 kg), and sumatriptan 20 mg and rizatriptan 10 mg for those weighing 40 
kg or more. 
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6. Randomization
Study II. Study drugs and the placebo nasal spray were provided by 
GlaxoSmithKline (GSK). The 10-mg and 20-mg sumatriptan and placebo 
nasal sprays were indistinguishable from one another. GSK packed and 
labeled the study drugs in accordance with a randomization schedule. 
Randomization was done in the Hospital Pharmacy at Helsinki University
Central Hospital by a pharmacist specialized in preparing drugs for clinical 
trials, but who was not involved in the study. A simple randomization plan 
generated manually (coin toss method) was used to assign the order 
(sumatriptan/placebo or placebo/sumatriptan) of each sequentially numbered
pair of treatments. The randomization was stratified by dosage (10 and 20 
mg).
Study III. Rizatriptan was a commercial product approved for use in adults 
in Finland (Maxalt?, 5 and 10 mg, Merck&Co). Because a matching placebo
was not available, study drugs were packed in capsules for blinding purposes. 
All capsules were indistinguishable from one another. The Hospital 
Pharmacy provided, packed, and labeled study drugs in accordance with a
randomization schedule. Randomization was done in the Hospital Pharmacy
at Helsinki University Central Hospital by a pharmacist specialized in 
preparing drugs for clinical trials, but who was not involved in the study. A 
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simple randomization plan generated manually (coin toss method) was used 
to assign the order (rizatriptan/rizatriptan/placebo,
rizatriptan/placebo/rizatriptan, or placebo/rizatriptan/rizatriptan) of each 
sequentially numbered set of treatments. The randomization was stratified by 
dosage (5 and 10 mg).  
7. Evaluation of efficacy and adverse effects (Studies II and III) 
Headache severity was chosen as the main efficacy variable. The intensity of 
headache was recorded in a headache diary by using a five-face scale (5 = 
severe, 3-4 = moderate, 2 = mild, 1 = no pain), which has been validated in 
children over four years of age (Figure 2) (Maunuksela et al. 1987) 
(Appendix B and C). Children were asked to record the pain intensity 
immediately before the treatment, and at 15, 30, and 60 minutes thereafter, 
continuing hourly for up to seven hours unless the child fell asleep or the 
symptoms resolved. Furthermore, one and two hours after treatment, the 
child was asked to assess whether the headache was the same, worse, milder, 
or absent compared with the initial situation. Headache diaries were filled in 
by the children themselves. In addition, parents were asked to assess their 
child’s behavior in a questionnaire covering nausea, mobility, falling asleep, 
and complaints of pain. Diaries were returned to the investigator at a follow-
up visit or by mail.  
Primary endpoint. The primary efficacy endpoint was headache relief from 
severe or moderate pain (? grade three) to at least two grades lower two 
hours after medication. Treatment was classified as successful when pain 
intensity decreased by at least two grades in the first two hours or the child 
fell asleep during these two hours and was pain-free upon awakening. 
Treatment was classified as a failure when pain increased or remained 
unchanged, decreased by only one grade, or rescue medication was used 
within two hours.
Secondary endpoints. Secondary endpoints were two-grade headache relief 
at one, three, and four hours after treatment, complete headache relief at one, 
two, three, and four hours, the child’s preference of treatments, and the use of 
rescue medication. If the child fell asleep and was pain-free upon awakening, 
the treatment was classified as successful at every time-point after falling 
asleep. If rescue medication was used, the treatment was classified as failure 
from that time onwards. The same criteria were used when complete pain-
free response was assessed. A sleeping child was classified to be pain-free 
only after waking up without pain. Age and gender may influence the natural 
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course of migraine, and thus, their effects on treatment response were also 
analyzed.
Evaluation of adverse effects. Children and their parents were asked to 
observe any adverse events after treatments and report them in the diaries. 
They were offered the contact information of the investigator to use in any 
unexpected situation.
8. Power calculations
Study II. Sample size calculation was based on estimated response rates in 
previous adult trials. Expected response rates were as follows: response to 
sumatriptan 60%, response to placebo 40%, response to sumatriptan without 
response to placebo 36%, and response to placebo without response to 
sumatriptan 16%. To detect a difference with a power of 80%, a significance 
level of 5%, and with an estimated drop-out rate of 20-30%, 120-130 patients 
were required to participate in the trial (Hills et al. 1979).
Study III. Sample size calculation was based on estimated response rates in 
previous adult trials and the response rates in Study II. Expected response 
rates were as follows: response to rizatriptan 60%, response to placebo 40%, 
response to rizatriptan without response to placebo 36%, and response to 
placebo without response to rizatriptan 16%. Furthermore, the three-way 
cross-over arrangement was estimated to raise the sample size needed by 
20%. To detect a difference with a power of 80%, a significance level of 5%, 
and an estimated drop-out rate of 20-30%, 150 patients were required to 
participate in the trial (Hills et al. 1979).
9. Statistical analyses  
The level of statistical significance in all studies and analyses was set at 
p<0.05.
Study I. Frequency differences in falling asleep in different age and gender 
groups were analyzed with analysis of variance (ANOVA). The confounding 
effect of missing data was analyzed with analysis of covariance (ANCOVA). 
The connection between falling asleep and attack duration was evaluated 
with ?2- test. The difference between mean ages was tested with the t-test. 
Study II. Children who gave complete data about pain intensity after both 
treatments were included in the primary efficacy analysis. All children who 
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used at least one treatment were included in the intention-to-treat analysis. 
Primary efficacy analysis was done with the McNemar nonparametric test for 
two related samples. Preference and use of rescue medication were analyzed 
with the sign test. In the intention-to-treat analysis, Generalized Estimating 
Equation (GEE) analysis (SAS, version 8.1) was applied to calculate 
differences between the two treatments, and the p-values were then adjusted 
for period effect. GEE analysis was also used to analyze the effect of age, 
sex, and treatment period on the response to sumatriptan and placebo. The 
unpaired data of the first treatment period were analyzed by logistic 
regression for binary responses. The T-test was used to compare the mean 
ages of responders and nonresponders to sumatriptan and placebo. 
Study III. Children who gave complete data about pain intensity after all 
three treatments were included in the primary efficacy analysis. All children 
who used at least one treatment were included in the intention-to-treat 
analysis. The results of the primary efficacy analysis and the intention-to-
treat analysis were analyzed separately using logistic models for multiple 
observations per individual, and were estimated by the GEE method (a 
logistic model). Stability of the treatment effect in consecutive migraine 
attacks was analyzed with a model containing the main effects of treatment 
and period and their interaction term. The effects of treatment, sequence of 
treatment (rpr, rrp, or prr), period (first, second, or third attack), and carry-
over effect in the three-period cross-over design were analyzed to compare 
the effects of rizatriptan and placebo. The treatment effects between 
rizatriptan and placebo at different time-points (1, 2, 3, and 4 hours) were 
compared by McNemar´s nonparametric test for two related samples. In the 
intention-to-treat analysis, the treatment effects between rizatriptan and 
placebo at different time-points were tested by logistic regression for binary 
responses. The effects of age and sex and the usage of rescue medication 
were analyzed by logistic regression in both primary efficacy and intention-
to-treat analyses. The difference between the mean ages of responders and 
nonresponders to rizatriptan and placebo was tested by the t-test. 
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RESULTS
1. Frequency of falling asleep during migraine attacks (Study I) 
Altogether 999 migraine attacks were registered in the diaries of 133 patients. 
The mean number of attacks registered by one patient was 7.5 (range 1-49). 
The visual analog scale (VAS) was used in 409 attacks, and the five-face 
scale in 590 attacks. The VAS was chosen by older children (mean age 12.1, 
range 7.6-16.9 years, n=66) than the face scale (mean age 9.5, range 4.6-15.3 
years, n=59) (t-test, P<0.0001). Eight patients used both scales. The median 
maximum pain intensity of all registered attacks was five on the face scale, 
and 94 on the VAS. The distribution of the maximum pain intensity was 
similar in both scales.  
A total of 329 attacks (32.9%) ended in falling asleep. In 431 attacks 
(43.1%), the pain resolved without sleep, and in 239 attacks (23.9%) the 
mode of headache relief was not adequately reported, mostly because the 
duration of the attack exceeded the five-hour follow-up (n=143, 14.3% of all 
attacks).  
Table 6 presents the sleep frequencies in different age groups. Falling asleep 
was more common in children under eight years of age than in older patients 
(ANOVA, p<0.0001), and it was especially common in girls of this age 
group (girls 70% vs. boys 53%). No significant differences were present in 
sleep frequencies between older age groups, nor were there age- or gender-
related differences in children over eight years of age. Sleeping was more 
common at the beginning of the attack; in 126 attacks (38%), the child ended 
up sleeping within the first 30 minutes, in 83 attacks (25%) between 30 
minutes and one hour, in 55 attacks (17%) between one and two hours, and in 
only 65 attacks (20%) after two hours´ observation time. Complete headache 
relief during the first two hours was more likely in children who slept than in 
those who did not (80% vs. 38%; ?2, p<0.0001).
Table 6. Falling asleep during migraine attacks in different age groups. Sleep frequency is 
defined as the proportion (%) of attacks relieved by sleeping in a single patient. 
No. of patients No. of attacks with sleep/ 
Total no. of attacks
Sleep frequency, 
mean
< 8 years 24 118/209 (57%) 62% 
8-12 years 62 166/503 (33%) 34% 
> 12 years 47 45/287 (16%) 24% 
Results
Of the attacks that resolved without sleep (n=431), 165 (38%) resolved 
within the first 2 hours, 218 (51%) between 2 and 4 hours, and 48 (11%) in 
over 4 hours. The study did not analyze the effects of any drug administered,
as the main purpose was to see what happens in a real situation at home.
Almost all children (n=125/133) used drugs at least in some attacks; the 
number of drugs varied between one and six.
2. Efficacy of nasal sumatriptan (Study II) 
Altogether 129 patients were recruited to the study, and 94 of these returned 
their headache diaries. Of these patients, 83 used both treatments and 11 used 
only the first one (sumatriptan n=7; placebo n=4). Patients who used both 
treatments were included in the primary efficacy analyses (n=83), and all 
patients who used at least one treatment were included in the intention-to-
treat analyses (n=94). Table 7 provides the number of patients, their mean
ages, and the mean doses in both treatment groups.
Table 7. Number, mean age, mean weight, and mean dose of patients in each treatment 
subgroup in Studies II and III.
No. of subjects 
(male, female) 
Mean age, 
years (range) 
Mean weight, 
kg (range) 
Mean dose, 
  mg/kg, (range)
Sumatriptan 94 (M 51, F 43) 12.4 (8.1-17.5) 46.7 (22.5-100) 0.36 (0.20-0.50)
 10 mg 31 (M 18, F 13) 10.3 (8.3-13.8) 31.2 (22.5-37.0) 0.33 (0.27-0.44)
 20 mg 63 (M 33, F 30) 13.4 (8.1-17.5) 54.3 (40.0-100.0) 0.38 (0.20-0.50)
Rizatriptan 116 (M 52, F 64) 12.0 (6.1-16.1) 45.0 (22.5-84.0) 0.18 (0.12-0.25)
 5 mg 48 (M 20, F 28) 9.9 (6.1-13.9) 31.8 (22.5-39.5) 0.16 (0.13-0.22)
 10 mg 68 (M 32, F 36) 13.5 (10.2-16.1) 54.8 (40.0-84.0) 0.19 (0.12-0.25)
2.1. Primary efficacy analysis. The primary efficacy endpoint (headache 
relief by two grades on the five-face scale at two hours) was reached clearly 
more often after sumatriptan than after placebo. Sumatriptan was superior to
placebo at already one hour postdose, and it retained its superiority over the
four-hour follow-up. Table 8 summarizes the response rates of sumatriptan
and placebo in all treated attacks. At two hours, 31% (n=26/83) after 
sumatriptan and 20% (n=17/83) after placebo were completely pain-free
(p=ns). Moreover, 13% (n=11/83) of children after sumatriptan and 12% 
(n=10/83) after placebo were sleeping at two hours and were pain-free upon 
waking. Pain-free response rates are summarized in Table 9.
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Sumatriptan was preferred by 57% (n=47/83) of children and placebo was by 
33% (n=27/83) (p=0.03); and 9 were undecided. Rescue medication was 
taken by 35% (n=29/83) after sumatriptan, and by 51% (n=42/83) after 
placebo (p=0.10). The treatment period had no effect on response to either 
sumatriptan or placebo. There were no differences in pain intensities of the 
attacks before administration of sumatriptan and placebo, but pain intensity 
in the attacks treated with sumatriptan 20 mg and placebo appeared to be 
higher than in the attacks treated with sumatriptan 10 mg (i.e. a higher 
proportion of patients recorded grade 4 or 5 on the five-face scale; 78 vs. 
64%). Age, gender, or puberty stage of the child did not have an impact on 
the response to sumatriptan. Young age slightly increased the positive 
response to placebo (mean age 11.74 years for placebo responders vs. 12.71 
years for nonresponders at two hours; p=0.07), but gender or puberty stage 
had no effect on response to placebo. The efficacy rates were similar in 
children receiving 10-mg and 20-mg treatments. Headache recurrence after 
initial relief was reported by four children after sumatriptan and by four 
children after placebo.
Table 8. Headache relief by two grades in 83 children after sumatriptan and placeboS in 
Study II and in 96 patients after rizatriptan and placeboR in Study III. Primary efficacy 
analyses. Difference from placebo, * p<0.001; ? p? 0.01. 
1 hour 2 hours 3 hours 4 hours 
Sumatriptan 42/83 (51%)? 53/83 (64%)? 55/83 (66%)? 56/83 (67%)?
PlaceboS 24/83 (29%) 32/83 (39%) 37/83 (45%) 39/83 (47%) 
1st Rizatriptan 48/96 (50%)? 71/96 (74%)* 79/96 (82%)* 80/96 (83%)* 
2nd Rizatriptan 53/96 (55%)? 70/96 (73%)* 73/96 (76%)* 73/96 (76%)* 
PlaceboR 28/96 (29%) 35/96 (36%) 39/96 (41%) 42/96 (44%) 
2.2. Intention-to-treat analysis. All 94 children who used at least one 
treatment were included in the analyses. Altogether 90 children received 
sumatriptan (10 mg, n=29; 20 mg, n=61) and 87 placebo. Sumatriptan was 
superior to placebo already 30 minutes after treatment (headache relief, 
n=28/90 (31%) vs. n=14/87 (16%), p=0.03), and even more clearly thereafter 
(Table 10). No significant difference was present in complete pain-free 
response, as 32% (n=29/90) of patients after sumatriptan, and 21% (n=18/87) 
after placebo were pain-free at two hours. Rescue medication was taken more 
often after placebo (51%; n=44/87) than after sumatriptan (32%; n=29/90) 
(p=0.03).
Results
Some children had detected a taste difference between sumatriptan and 
placebo nasal spray, which could have caused unblinding of the treatments,
and thus affecting the results of the second treatment period. Although 
statistical analyses revealed no sign of a period or carry-over effect, the 
results of the first period alone were also analyzed. The superiority of 
sumatriptan was even more obvious in this analysis. The primary efficacy
endpoint was reached at one hour in 50% (n=23/46) of attacks after 
sumatriptan and in 21% (n=10/48) after placebo (p=0.004), and at two hours 
in 74% (n=34/46) of attacks after sumatriptan, and in 33% (n=16/48) after 
placebo (p<0.001).
2.3. Adverse effects. Adverse effects were reported by 41 of 94 patients 
(44%) and in 35 of 90 attacks (39%) after sumatriptan and 7 of 87 attacks
(8%) after placebo. No serious adverse effects were observed. Bad taste of 
the drug was the most commonly reported complaint (n=30/90 (33%) attacks 
after sumatriptan, n=5/87 (6%) after placebo; p<0.001). Other reported 
adverse effects were vomiting together with a bad taste (three after
sumatriptan, one after placebo), nausea together with a bad taste (one after 
sumatriptan), nausea (two after sumatriptan, one after placebo), abdominal
pain (one after placebo), stiffness in jaws (one after sumatriptan), and feeling 
of lightheadedness (two after sumatriptan). The incidence of adverse effects
was similar in gender and age groups, but more children taking sumatriptan
20 mg experienced adverse effects than those taking sumatriptan 10 mg (44% 
vs. 28%).
Table 9. Complete pain-free response in 83 children after sumatriptan and placeboS in Study
II and in 96 patients after rizatriptan and placeboR in Study III. Primary efficacy analyses.
Difference from placebo; ?p< 0.05.
1 hour 2 hours 3 hours 4 hours
Sumatriptan 15/83 (18%) 26/83 (31%) 38/83 (45%) 42/83 (51%)
PlaceboS 11/83 (13%) 17/83 (20%) 27/83 (33%) 37/83 (45%)
1st Rizatriptan 14/96 (15%) 34/96 (35%)? 44/96 (46%)? 48/96 (50%)?
2nd Rizatriptan 13/96 (14%) 30/96 (31%)? 40/96 (42%)? 42/96 (44%)?
PlaceboR 10/96 (10%) 17/96 (18%) 17/96 (18%) 21/96 (22%)
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Table 10. Headache relief by two grades in 90 attacks after sumatriptan, and in 87 attacks
after placeboS (Study II) and in 212 attacks after rizatriptan and 106 attacks after placeboR
(Study III). Intention-to-treat analyses. Difference from placebo, * p<0.001; ? p? 0.01.
1 hour 2 hours 3 hours 4 hours
Sumatriptan 48/90 (53%)? 60/90 (67%)* 62/90 (69%)? 63/90 (70%)?
PlaceboS 25/87 (29%) 33/87 (38%) 40/87 (46%) 42/87 (48%)
Rizatriptan 109/212 (51%)* 152/212 (72%)* 164/212 (77%)* 164/212 (77%)*
PlaceboR 30/106 (28%) 41/106 (39%) 45/106 (43%) 48/106 (45%)
3. Efficacy of rizatriptan (Study III)
Altogether 147 patients were recruited to the study. Of these, 96 used all 
three treatments, 10 used two treatments (rizatriptan, n=13; placebo, n=7), 10 
used one treatment (rizatriptan, n=7; placebo, n=3), and 31 used no 
treatments. Patients who used all three treatments were included in the 
primary efficacy analyses (n=96), and all patients who used at least one 
treatment were included in the intention-to-treat analyses (n=116). Table 7 
summarizes the number of patients, their mean ages, and the mean doses in
the treatments groups (5 and 10 mg).
3.1. Primary efficacy analysis. The primary efficacy endpoint at two hours
was reached twice as often after both treatments of rizatriptan as after 
placebo. Both doses of rizatriptan were superior to placebo at already one 
hour postdose, and remained superior over the four-hour follow-up. Table 8 
summarizes the response rates in all treated attacks. Those children who slept 
at the current time-point and were pain-free or markedly relieved upon 
awakening were classified as having a positive treatment response (at two 
hours: 16 patients after the first rizatriptan, 15 patients after the second 
rizatriptan, 10 patients after placebo). Even had these sleeping children been
classified as having a treatment failure, rizatriptan would have remained
superior to placebo in this analysis (p<0.001 at two hours). No difference was
found in total pain-free response after rizatriptan and placebo at one hour, but 
from two hours onwards both doses of rizatriptan were numerically and 
statistically more effective than placebo in giving complete painlessness.
Pain-free response rates are shown in Table 9. The effect of rizatriptan 
remained very stable over the two treated attacks.
Rescue medication was taken by 18% (n=17/96) and 22% (n=21/96) of 
patients after the first and the second dose of rizatriptan, and by 40% 
(n=38/96) of patients after placebo (p=0.004 and p=0.017 between 1st and 2nd
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rizatriptan and placebo, respectively). Treatment was classified as excellent 
or good by 52% (n=50/96) and 53% (n=51/96) of children after the first and 
the second dose of rizatriptan, but only by 34% (n=33/96) after placebo 
(p=0.015 and p=0.014 between 1st and 2nd rizatriptan and placebo). No 
difference existed in pain intensity before administration of rizatriptan and 
placebo. Nor was there a difference in pain intensity in attacks treated with 
rizatriptan 10 mg compared with those treated with 5 mg. Before the first and 
the second treatment with rizatriptan, 63% (n=60/96) and 75% (n=72/96) of 
patients, respectively, reported headache intensity as being grade 4 or 5 on 
the five-face scale; 72% (n=69/96) of patients before placebo reported the 
same. 
No carry-over, period, or sequence effect was detected by GEE analysis. Sex 
had no impact on response to rizatriptan or placebo. When attack was first 
treated with rizatriptan, children reporting headache relief at two hours were 
younger than nonresponders (mean age 11.56 years for responders vs. 13.22 
for nonresponders; P=0.003). Similarly, younger children who used 
rizatriptan 5 mg tended to benefit more from treatment in the first rizatriptan 
period than did those who used the 10-mg dose (log reg, p=0.014). The same 
effect was not seen in the second period of rizatriptan. Age otherwise did not 
have an effect on response to rizatriptan or placebo, and the results were 
similar in children receiving the 5-mg and 10-mg doses.  
3.2. Intention-to-treat analysis. All 116 children who used at least one 
treatment were included in the analysis. Altogether 212 attacks were treated 
with rizatriptan and 106 attacks with placebo. Rizatriptan dose was 10 mg in 
123 attacks and 5 mg in 89 attacks. The two-grade headache relief was 
reached in 51% (n=109/212) of attacks after rizatriptan, and in 28% 
(n=30/106) of attacks after placebo one hour postdose (p<0.001). Rizatriptan 
was superior to placebo also at two, three, and four hours thereafter; response 
rates are listed in Table 10. Younger children reported headache relief more 
often after rizatriptan (mean age 11.70 years for responders vs. 12.71 years 
for nonresponders; p=0.008). There was no similar difference in response to 
placebo. No difference was found in complete pain-free response after 
rizatriptan (painless; 14%, n=29/212) and placebo (9%, n=10/106) one hour 
after treatment (p=0.28). However at two hours, pain-free response was more 
often reached after rizatriptan (32%, n=67/212) than after placebo (18%, 
n=19/106)(p=0.011). Rescue medication was taken by 22% (n=47/212) of 
patients after rizatriptan and by 40% (n=42/106) after placebo (p=0.001).
Headache recurrence after initial relief was reported after 5% (n=10/212) of 
Results
67
attacks treated with rizatriptan and after 4% (n=4/106) of attacks treated with 
placebo (p=0.70).
The results of the first treatment period were also analyzed separately to 
exclude any period effect, although no period or carry-over effect was 
detected in GEE analysis. Rizatriptan was more effective than placebo in 
relieving headache already at one hour (rizatriptan 43%, n=34/79 vs. placebo 
24%, n=9/37; p=0.055), even more clearly at two hours (rizatriptan 68%, 
n=54/79, placebo 41%, 15/37; p=0.005), and remained superior to placebo 
also at three and four hours.
3.3. Adverse effects. Adverse effects were reported by 14% of all patients 
(n=16/116), in 9% of attacks (n=20/212) after rizatriptan and 2% of attacks 
(n=2/106) after placebo (p=0.025). No serious adverse effects were observed. 
Four patients reported similar adverse effects after both treatments of 
rizatriptan: one experienced tiredness and dry mouth, one felt a burning 
sensation in the head, one had flushed cheeks, and one had pain in the ankles. 
Six children who used both treatments of rizatriptan reported adverse effects 
after the first rizatriptan, but not after the second (one reported tiredness, one 
nausea, one faintness and nausea, one had flushed cheeks, one had pain in the 
cheeks, and one pressure in the throat). Five children who used both 
treatments of rizatriptan reported adverse effects after the second rizatriptan, 
but not after the first (three reported tiredness, one vomiting, and one 
pressure in the throat, cheeks, and head). Furthermore, one child who used 
only one rizatriptan reported feeling strange after the treatment. Two children 
experienced adverse effects after placebo (one reported tiredness, and one 
vomiting). No differences in the incidence of adverse effects were observed 
for sex and age groups; however, slightly more children taking the 10-mg 
dose of rizatriptan experienced adverse effects than those taking the 5-mg 
dose (12% vs. 6%; p=0.12). 
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DISCUSSION
1. Sleep and migraine  
Sleep and migraine certainly seem to be related in many respects. Sleep can 
either relieve or induce migraine headaches. Insufficient sleep is a well-
known headache trigger, and children with migraine have reported more 
sleep disturbances, such as difficulties in falling asleep, daytime sleepiness, 
night-awakenings, bruxism, and snoring, than healthy controls. The extent of 
sleep disturbance correlated well with the severity of the migraine symptoms 
(e.g. frequency, pain intensity) (Miller et al. 2003, Gilman et al. 2007), but 
whether headache leads to sleep disturbance or sleep disturbance leads to 
headache or whether these are separate entities, remains obscure. The role of 
sleep in the resolution of headache and as part of the natural healing process 
of migraine attack in both adults and children has long been known. The 
observation that sleep resolves migraine attacks was first made over 100 
years ago by Liveing (Liveing 1873, Blau 1982).  
Sleep and resting were cited as the primary treatment option for migraine by 
28% of Canadian children; of these only one-third used pain medication 
during a 10-year follow-up time (Dooley et al. 1995). In our study, nearly all 
patients used pain medication, mainly NSAIDs or paracetamol (125/133), the 
effect of which was not analyzed further. Patients had all been referred to 
specialized healthcare by a general practitioner (GP). They probably suffered 
from more complicated disease and most likely more often used pain 
medication than those children who managed with GP treatment, or even 
without healthcare consultation. Sleep and resting without drug treatment are 
probably effective and sufficient only in mild migraine attacks. Use of drugs 
likely did have an effect on headache duration and sleep frequency in Study I. 
However, the purpose of that study was to evaluate migraine-related sleep in 
a real clinical situation, where most patients at least occasionally use pain 
medication.  
According to Study I, falling asleep during a migraine attack happens very 
frequently. Most children (68%) at least occasionally slept during a migraine 
attack. Sleeping was especially common during the first hour (64% of all 
attacks relieved by sleep), and those children who were able to sleep were 
more likely pain-free (80%) at two hours compared with those who did not 
(38%). A similar finding has been reported in adults; 50% of those who slept 
were pain-free at three hours compared with 31% of those who did not 
(Wilkinson et al. 1978).  
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In children younger than eight years, sleeping was more common than in 
older age groups. Over half of all attacks (57%) in this age group were 
relieved during sleeping, the mean sleep frequency (defined as the proportion 
of attacks relieved by sleep in a single patient) being 62%. This was even 
more pronounced in girls (70%). No sleep frequency difference was observed 
between children aged 8-12 years (34%) and those over 12 years (24%). The 
lower tendency for sleep in older children might be explained by stronger and 
longer attacks, as headaches in general have been reported to disturb sleep 
(Bruni et al. 1997). In  Study I, although the median maximum pain intensity 
was high and comparable in both VAS and face scale, the attacks registered 
with VAS appeared to generally be more painful than attacks registered with 
face scale. In addition, the duration of attacks registered with VAS more 
often exceeded the five-hour registration maximum of the headache diary 
(22% of all attacks registered with VAS) than those registered with the face 
scale (9% of all attacks registered with face scale). Children who chose to use 
VAS were older than children who used face-scale (mean ages 12.1 and 9.5 
years, respectively), thus, older children appear to have more painful and 
longer attacks than younger children. A similar trend has been reported in 
previous trials (Mortimer et al. 1992a, Wöber-Bingöl et al. 2004). Overall, 
pain intensity and duration of migraine attacks seem to increase with age, and 
these may be linked to a lower tendency for falling asleep during an attack.
In drug studies of sumatriptan and rizatriptan (Studies II and III), falling 
asleep was not as common as in the epidemiological study (Study I). In Study 
II, 13% of patients after sumatriptan and 12% after placebo were sleeping at 
two hours. In Study III, 17% and 16% after the first and second dose of 
rizatriptan, respectively, and 10% after placebo were sleeping at two hours. 
Lower values might be due to patients´ commitment to the study protocol, as 
they probably tried to stay awake to be able to fill out their headache diaries.  
Information about sleep related to migraine attacks in children is important in 
clinical drug trials and in drafting guidelines on the evaluation of migraine 
treatments in children, specifically on how to classify a sleeping child. Is it 
correct to assume that a child who falls asleep after a study drug has 
experienced headache relief, or should he/she be omitted from the analysis or 
be classified as a treatment failure because correct registration of pain 
intensity has not been done. According to Study I, children and adolescents´ 
falling asleep during migraine attacks is so frequent, that results would be 
distorted if a sleeping child is automatically excluded from analyses or 
classified as a treatment failure. In Studies II and III (and in all previous trials 
of our study group), sleeping was assessed as being a sign of headache relief, 
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and thus, a sleeping child was classified as having a positive response to the 
study drug. As placebo responses remained constant and low (close to the 
values generally observed in migraine treatment trials with adults), falling 
asleep most likely reflects true headache relief. In considering the results of 
Studies I, II, and III, this seems to be the correct approach, and thus, can be 
recommended for future migraine treatment studies in children adolescents. 
This interpretation has recently also been adopted by The European 
Medicines Agency´s (EMEA), which recommended in its ´Guideline on 
clinical investigation of medicinal products for the treatment of migraine in 
children and adolescents´ that falling asleep at two hours after the study agent 
could be used as an efficacy endpoint in studies of acute treatment of 
migraine in children (European Medicines Agency 2006).  
Overall, sleep probably can provide headache relief without other treatments 
only in mild migraine attacks. It can, however, improve recovery from 
migraine attack when combined with drug treatment, and is also a sign of 
headache relief, as a severe headache impedes a patient from falling asleep.  
2. Efficacy of intranasal sumatriptan
Sumatriptan was more effective than placebo in relieving migraine pain 
already 30 minutes after treatment and remained superior throughout the 
follow-up. Two hours after medication, headache relief by two grades after 
sumatriptan was experienced nearly twice as often (64%) as after placebo 
(39%). No difference in response rates existed between sumatriptan 10 and 
20 mg. One-third of the patients (31%) were completely pain-free after 
sumatriptan at two hours; the response compared with after placebo (20%) 
was not, however, significant. Other endpoints favored sumatriptan, as 
children subjectively preferred sumatriptan over placebo, and also required 
less rescue medication after sumatriptan.  
Efficacy rates in Study II agree with efficacy rates of sumatriptan 20 mg 
nasal spray reported previously in adult studies. In these, headache relief 
response rates have generally ranged between 55% and 78%, and complete 
pain-relief response rates between 26% and 42% (Perry et al. 1998, Dahlof 
1999).
An earlier parallel-group study of 510 adolescents aged 12-17 years, 
compared sumatriptan nasal spray at doses of 5, 10, and 20 mg with placebo 
in the treatment of a single migraine attack. The response rates for headache 
relief at two hours were 66%, 64%, and 63%, respectively, and 53% for 
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placebo. As the placebo response rate was high, only the response to 
sumatriptan 5 mg reached statistical significance (Winner et al. 2000). 
Complete pain relief at two hours was achieved by 36% of patients after 
sumatriptan 20 mg and by 25% after placebo (p<0.05). The second trial by 
the same authors compared the efficacy of sumatriptan nasal spray 5 and 20 
mg with placebo in a parallel-group single-attack study in 738 adolescents 
aged 12-17 years (Winner et al. 2006). Sumatriptan 20 mg provided greater 
headache relief than placebo at 30 minutes and at two hours (42% and 68% 
after sumatriptan vs. 33% and 58% after placebo), but did not reach 
significance at one hour. The response rates after sumatriptan 5 mg were 
slightly higher than after placebo, but were not significant. Response rates to 
sumatriptan in both of these trials are of a similar magnitude to Study II. 
However, in our study, the placebo response rates were markedly lower, and 
consequently, the differences between placebo and active treatment were 
more obvious. In Study II, headache recurrence after initial relief was 
reported by only four children after sumatriptan (5%) and by four children 
after placebo (5%). That is clearly less than is generally seen in adults (30-
46%) (Dahlof 1999), and less than in two other studies in adolescents (16% 
and 24% after sumatriptan 20 mg) (Winner et al. 2000, 2006). The 
discrepancy with adult studies might be explained by shorter migraine attacks 
in children and adolescents than in adults. The reason for lower headache 
recurrence in Study II compared with other adolescent studies remains, 
however, unknown.
Only one placebo-controlled trial of efficacy of intranasal sumatriptan in 
children under 12 years has been published (Ueberall et al. 1999). This small 
two-way cross-over trial of 14 children aged 6-10 years, reported a headache 
relief response rate of 86% after sumatriptan 20 mg, and 43% after placebo at 
two hours postdose. Complete pain-free response at two hours was achieved 
by 64% after sumatriptan, and by 14% after placebo. Response rates were 
higher than in Study II and similar to those previously reported in two open-
label studies in children after subcutaneous sumatriptan (MacDonald 1994, 
Linder 1996). There was a clear methodological difference to Study II, as in 
our study a sumatriptan dose of 10 mg was mainly used in children under 10 
years of age (in children weighing less than 40 kg).
A cross-over study design allows a smaller sample size to be used, as patients 
serve as their own controls. This is especially advantageous when studying 
treatments in children since smaller number of subjects need to be 
predisposed to a treatment. Cross-over study designs have, however, the 
potential for period or carry-over effects, which could skew the results. In 
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Study II, this seemed unlikely according to the statistical analyses. Because 
one-third of the children could detect a taste difference between sumatriptan 
and placebo, we analyzed the results of the first treatment period alone to 
exclude the effect of possible unblinding of the treatments. In this analysis, 
sumatriptan was even more efficacious than in the primary efficacy analysis 
(headache relief rate of 74% at two hours), and response to placebo also 
remained unchanged (33%).  
3. Tolerability of intrasanal sumatriptan
Although Study II was not specifically designed to study the safety and 
tolerability of sumatriptan nasal spray, adverse effects were carefully 
recorded in headache diaries. Sumatriptan was well tolerated, and serious 
adverse effects were not observed. The most commonly reported adverse 
effect was a bad taste of the drug, which sometimes was followed by nausea 
and vomiting. Adverse effects after sumatriptan not connected to the bad 
taste of the drug were sporadic (n=5/90 attacks) and did not differ from those 
after placebo (n=2/87 attacks). Similar findings have been reported in all 
other sumatriptan nasal spray efficacy trials in children and adolescents 
(Ueberall et al. 1999, Winner et al. 2000, 2006), as well as in two one-year 
open-label tolerability trials where drug-related adverse effects (taste 
disturbance excluded) were observed in 4% and 7% of patients (Rothner et 
al. 2000, Natarajan et al. 2004). In Study II, children taking the 20-mg dose 
of sumatriptan (mean dose 0.38 mg/kg) reported more adverse effects than 
those taking the 10-mg dose (0.33 mg/kg) (44% vs. 28%). Also the other two 
adolescent trials reported similar findings, with overall incidence of adverse 
effects increasing with larger sumatriptan dosages (Winner et al. 2000, 2006). 
In one-year tolerability trial, drug-related adverse effects were similar after 
10-mg and 20-mg sumatriptan doses (33% and 31%, respectively) (Rothner 
et al. 2000).
4. Efficacy of rizatriptan  
Rizatriptan seemed to be highly effective in treating of migraine attacks in 
children and adolescents. At two hours after the first and second dose of 
rizatriptan, 74% and 73% of patients, respectively, experienced headache 
relief, and 35% and 31% achieved complete pain-free response. Headache 
relief and complete pain-free response were achieved by 36% and 18% of 
patients, respectively, after placebo. Both doses of rizatriptan were 
statistically superior to placebo in relieving headache from one hour onwards 
and offering a complete pain-free response from two hours onwards. The 
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results were similar in patients receiving the 5- and 10-mg doses; however, in 
the intention-to-treat analyses, younger children reported headache relief at 
two hours more often after rizatriptan than older children (mean age 11.70 
years for responders vs. 12.71 years for nonresponders). All other endpoints 
also favored rizatriptan, as rescue medication was needed more often after 
placebo, and children´s opinions of the treatment were more positive towards 
rizatriptan.  
Efficacy of rizatriptan in Study III was comparable with the response rates 
seen in previous trials in adults. In these, headache relief at two hours after 
rizatriptan 5 or 10 mg has generally been reported by 59-77% of patients 
(after placebo by 25-40%) (Dooley et al. 1999, Ferrari et al. 2001), and 
complete pain-free response by 25-44% (after placebo by 7-10%).  
Rizatriptan efficacy in Study III was of similar magnitude as in two previous 
placebo-controlled trials in adolescents. In these single-attack, parallel-group 
studies with rizatriptan 5 mg in patients aged over 12 years, headache relief 
was reported by 66% and 68.2% two hours postdose (Winner et al. 2002, 
Visser et al. 2004). However, no statistical benefit of rizatriptan was shown 
because of the high placebo response rates of 56% and 68.8%. Interestingly, 
the placebo response was lower when attacks were treated on weekends (36% 
and 58%), and statistically superior headache relief to placebo was reached 
by rizatriptan. The authors suggested that the reason for this difference was 
probably delayed treatments on schooldays, and thus, spontaneous attack 
relief by the time the study drug was administered. Overall, headache relief 
response rates at two hours after rizatriptan were slightly higher in Study III 
than in these two other studies. This might be explained by the higher 
rizatriptan dose of 10 mg that was mainly used in children over 12 years of 
age (for those weighing over 40 kg) in our study. Headache recurrence after 
initial relief in Study III was rare, reported by 5% of children after rizatriptan,
and by 4% after placebo. This is slightly less than the figure reported in the 
other adolescent trial (14%)(Winner et al. 2002) and markedly lower than 
that seen in adult rizatriptan trials (29-47%)(Jhee et al. 2001).
Our study was designed to test not only the efficacy of rizatriptan, but also 
the consistency of response over two treated migraine attacks. As in the adult 
placebo-controlled study with three or four attacks treated with rizatriptan 
(Kramer et al. 1998), efficacy in Study III was consistent over the two treated 
attacks. There was no sign of tolerance to the therapeutic effect of rizatriptan. 
In two open-label multiple-attack one-year studies in adolescents aged 12-17 
years treated with rizatriptan 5 mg (tablet or wafer), the two-hour headache 
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relief response also remained constant over the treated attacks; the overall 
response rate was 77% (Visser et al. 2004). Similar findings have been 
reported in adults with long-term use of rizatriptan (Gobel et al. 2001).
Rizatriptan is absorbed rapidly, which offers a therapeutic benefit when 
treating children and adolescents, who generally have shorter migraine 
attacks than adults. In Study III, rizatriptan was encapsulated for blinding 
purposes, which might have delayed the onset of the therapeutic action of the 
drug. Encapsulation of sumatriptan tablets has previously been demonstrated 
to increase the median time to meaningful headache relief by 17 minutes in 
adults (Fuseau et al. 2001). As the maximum concentration of rizatriptan 
during and between migraine attacks is achieved in one hour in adults (Cutler 
et al. 1999, Lee et al. 1999), this potential delay in absorption likely did not 
affect the results markedly at two hours postdose or later. In addition, any 
effect of the encapsulation on rizatriptan absorption most likely would lead to 
underestimation of efficacy. Another methodological concern in the cross-
over study design is a possible period effect on results. Although statistical 
analyses revealed no sign of period or carry-over effect, the results of the first 
treatment period alone were analyzed as in the previous Study II. Also in this 
analysis rizatriptan was superior to placebo at one hour and thereafter, 
headache relief rates at two hours being 68% for rizatriptan and 41% for 
placebo.
5. Tolerability of rizatriptan  
Like the sumatriptan study, Study III was not specifically designed to 
investigate the safety and tolerability of rizatriptan, but adverse effects were 
again very carefully recorded in the headache diaries. Adverse effects were 
reported in 9% of the attacks after rizatriptan and in 2% of the attacks after 
placebo. Slightly more adverse effects were reported after rizatriptan 10 mg 
(mean dose 0.19 mg/kg; 12%) than after 5 mg (0.16 mg/kg; 6%). Adverse 
effects were mild in nature, and rizatriptan seemed to be well tolerated in all 
age groups. Four patients reported similar adverse effects after both 
treatments of rizatriptan. If encapsulation affected the rate or extent of 
rizatriptan absorption, it could have led to an underestimation of the adverse 
effects.
Rizatriptan 5 mg was well tolerated also in another controlled adolescent 
trials (Winner et al. 2002, Visser et al. 2004) as well as in two one-year 
multiple-attack trials (Visser et al. 2004). Adverse effects in controlled trials 
were reported by 34% and 30% of patients after rizatriptan and by 35% and 
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25% of patients after placebo, respectively. The most commonly reported 
adverse effects were asthenia, dizziness, dry mouth, and somnolence. The 
incidence of drug-related adverse effects was comparable with that reported 
in adults, and did not differ from that of placebo or standard care (Wellington 
et al. 2002, Visser et al. 2004).
6. Placebo response and migraine  
The placebo response rates in clinical trials in children and adolescents with 
migraine have generally been much higher than the figures reported in adult 
studies. One probable reason for this is that migraine attacks in children and 
adolescents are shorter than in adults, and thus, spontaneous recovery rates 
are faster. A high placebo response rate renders detection of the true 
difference between active treatment and placebo more challenging. In US-
based trials with sumatriptan nasal spray and rizatriptan, the response rates to 
active treatments have been similar to those in Studies II and III, and also 
similar to those seen in adults, but placebo responses have been so high, 
especially in rizatriptan studies, that a statistical difference has failed to 
emerge (Winner et al. 2002, Visser et al. 2004). In nasal sumatriptan studies, 
a significant difference to placebo has sometimes been reached, although 
placebo relief at two hours has repeatedly been over 50% (Winner et al. 2000, 
2006).
In our studies of nasal sumariptan (Study II) and rizatriptan (Study III), the 
placebo response remained very stable over the two studies. It was also in the 
same range as previously described in an ibuprofen-paracetamol trial 
conducted by our group with similar study methods (Hämäläinen et al. 
1997c). The placebo responses in these studies have generally ranged 
between 36% and 39%; these figures are about 10% higher than those in 
adult studies (Loder et al. 2005, Macedo et al. 2006).
Many factors may contribute to a placebo response rate: study design, the 
pain scale used, the study center, cultural aspects such as a child´s eagerness 
to please the doctor, a child´s previous experiences and expectations of 
migraine treatment, and other treatment interaction factors, e.g. delays in 
drug administration (Lewis et al. 2005, Fernandes et al. 2008). A 
methodological difference in Studies II and III compared with US studies, is 
that we used a five-face pain scale instead of the four-point validated rating 
scale preferred in the US ones. The five-point scale may be more sensitive in 
distinguishing pain level in children, and thus, would be more suitable for use 
in trials with children. In our studies, falling asleep was classified as a sign of 
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headache relief. This seems to be the correct approach, as it does not lead to 
elevated placebo response rates. The US studies had a parallel study design, 
in contrast to Studies II and III, which had a cross-over design. Trials with 
parallel design have reported overall higher placebo response rates than those 
with cross-over design; this has also been seen in adult studies (Macedo et al. 
2006). All children who participated in Studies II and III had rather severe 
migraine symptoms, which were not relieved by NSAIDs or paracetamol. 
This difference in the inclusion criteria offers one possible explanation for 
the overall lower placebo responses in Studies II and III than in American 
studies.
In pain treatment trials, children have generally shown elevated placebo 
response rates, and the response rate is suggested to be even more 
pronounced in adolescents (Goodenough et al. 1997). In Study II, placebo 
response was actually slightly higher in younger subjects. This may be 
explained by the shorter attacks of young children compared with 
adolescents, and especially in Study II, by the lower baseline severity of the 
attacks treated with sumatriptan 10 mg. The same age difference in placebo 
response was not seen in the rizatriptan study (Study III), nor was there a 
difference in pain intensity between attacks treated with rizatriptan 5 and 10 
mg. A recent review evaluating placebo response in 13 controlled trials of 
acute migraine treatment in children and adolescents (including Studies II 
and III of this work) also did not confirm a greater placebo response in 
younger children (Fernandes et al. 2008). One ibuprofen study has 
demonstrated a higher placebo response rate in girls (67%) than in boys 
(43%) (Lewis et al. 2002b), but we found no sex difference in response to 
either placebo or active treatment.  
Recently, both physicians and parents have questioned the appropriateness of 
using placebo control groups in clinical drug trials with children (Caldwell et 
al. 2002, Caldwell et al. 2003, Linde et al. 2003, Caldwell et al. 2004). 
Migraine is a condition in which symptoms appear occasionally, and there is 
no risk of the disease worsening or any effect on growth and development if 
symptoms remain untreated. There is probably a greater risk to children with 
migraine if ineffective or harmful drugs are approved without appropriate 
assessment in randomized trials than in a short-term use of a placebo in a 
carefully designed controlled trial (Emanuel et al. 2001, Linde et al. 2003).
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7. Clinical implications
Sleeping during migraine attacks is very common. It can both improve 
recovery from migraine attack when combined with a drug treatment, and 
serve as a sign of headache relief, as a severe headache impedes a patient 
from falling asleep. Findings in Studies I, II and III support that falling asleep 
should be classified as a sign of headache relief in clinical drug trials with 
children and adolescents. Distortion of results would likely occur if a 
sleeping child is automatically excluded from analyses or classified as a 
treatment failure. In Studies II and III, this approach was successfully 
adopted, as placebo response remained low, suggesting that falling asleep 
probably reflects true headache relief. 
The current standard treatment for migraine attacks in children and 
adolescents is NSAIDs, especially ibuprofen (10 mg/kg; maximum dose 40 
mg/kg/day) and paracetamol (15 mg/kg; maximum dose 60 mg/kg/day). 
Paracetamol is slightly more rapid in action, but the overall efficacy of 
ibuprofen seems to be better (Hämäläinen et al. 1997c). At two hours, 60% of 
patients were completely pain-free after ibuprofen.  
Study II and also other published data (Winner et al. 2000, 2006) suggest that 
sumariptan nasal spray can be safely and effectively used at the adult dose 
(20 mg) to treat migraine attacks in adolescents aged over 12 years. Nasal 
sumatriptan could be beneficial particularly in children who need more 
effective drugs than NSAIDs. Sumatriptan nasal spray is especially useful 
when nausea or vomiting occurs and oral administration of drugs is not 
desirable. Nasal sumatriptan 10 mg is now licensed in the European Union 
for treatment of migraine attacks in adolescents over 12 years of age; one of 
the pivotal studies for approval was Study II of this thesis. No difference was 
observed in efficacy or safety of nasal sumatriptan between children aged 8-
12 years and older children in Study II, but because relatively few children in 
the younger age group have participated in controlled trials to date, the 
efficacy and safety is not well documented and further studies are reqiuired.  
In Study III, rizatriptan was found to be an effective and well-tolerated 
treatment for migraine attacks in children over six years of age and 
adolescents. Treatment effect remained stable over two consecutive attacks. 
Two other controlled trials have reported good efficacy rates of rizatriptan 5 
mg in adolescents aged over 12 years, although the high placebo response did 
prevent emergence of statistical significance (Winner et al. 2002, Visser et al. 
2004). In two open-label multiple-attack studies, also the tolerance of 
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rizatriptan 5 mg in adolescents was good (Visser et al. 2004). In Study III, the 
rizatriptan dose for adolescents weighing over 40 kg was 10 mg, which 
seemed to offer more efficacy than the 5-mg dose and a similar adverse effect 
rate. Study III suggests that rizatriptan could be safely and effectively used to 
treat migraine attacks in adolescents aged over 12 years. Neither the efficacy 
nor the tolerance of rizatriptan in children from 6 to 12 years of age differed 
from that of older children. The number of patients and attacks treated in this 
age group is, however, small, and more studies are needed before the efficacy 
and safety can be ensured and rizatriptan can be recommended to wider use. 
When the efficacy of nasal sumatriptan and rizatriptan are compared, 
rizatriptan appears to be slightly more effective (about 10% from two hours 
onwards). The complete pain-free response after rizatriptan also reached 
statistical significance compared with placebo; however, the pain-free 
response rates in percentages after rizatriptan and sumatriptan were quite 
similar. Head-to-head comparisons are impossible to do based on only these 
two studies, and, as in adults, pain relief response to triptans can vary greatly 
between children. Moreover, many other individual factors and migraine 
characteristics need to be considered in choosing an optimal migraine therapy 
for each child. It would be important, however, to also get oral triptan 
licensed for children and adolescents as an alternative to sumatriptan nasal 
spray, as many children dislike using an intranasal spray because of the bad 
taste.
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CONCLUSIONS
Study I: Sleeping during migraine attacks is very common. Most affected 
children (68%) at least occasionally sleep during an attack. Falling asleep is 
especially common during the first hour after attack onset. Children who are 
able to sleep soon after attack onset are more likely pain-free at two hours 
than those who do not sleep. Sleeping probably both improves recovery from 
a migraine attack and signals headache relief. In children younger than 8 
years, sleeping is more common than in older age groups; over half of all 
attacks (57%) in this younger age group are relieved by sleeping. Pain 
intensity and duration of migraine attacks seem to increase with age, and 
these may be factors explaining a lower tendency for falling asleep during an 
attack. Children and adolescents fall asleep during a migraine attack so 
commonly that distortion of results would likely occur in clinical drug trials 
if a sleeping child is automatically excluded from analyses or classified as a 
treatment failure. Falling asleep should be classified as a sign of headache 
relief in clinical drug trials of migraine treatments in children and 
adolescents.
Study II: Intranasal sumatriptan is more effective than placebo in relieving 
migraine headache one hour postdose and thereafter in children and 
adolescents aged 8-17 years. Headache relief by two grades on the five-face 
pain scale at two hours after sumatriptan (64%) was reported nearly twice as 
often as after placebo (39%). One-third of patients were pain-free at two 
hours, but the response was not statistically superior to placebo. Children 
subjectively preferred sumatriptan over placebo and required less rescue 
medication after sumatriptan. Intranasal sumatriptan was well tolerated, the 
most commonly reported adverse effect being its bad taste. No serious 
adverse effects were observed. Our results suggest that intranasal sumatriptan 
can be effectively and safely used at an adult dose of 20 mg to treat migraine 
attacks in adolescents aged over 12 years.     
Study III: Rizatriptan is clearly more effective than placebo in relieving 
migraine headache from one hour onwards in children and adolescents aged 
6-17 years. Headache relief by two grades on the five-face pain scale at two 
hours after both administrations of rizatriptan (74%,73%) was reported twice 
as often as after placebo (36%). Both doses of rizatriptan were superior to 
placebo in offering a complete pain-free response two hours postdose and 
thereafter. Response to rizatriptan remained very constant over two 
consecutive migraine attacks. Rescue medication was needed more often 
after placebo, and children subjectively preferred rizatriptan over placebo. 
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Rizatriptan was well tolerated, and no serious adverse effects were observed. 
Our results suggest that rizatriptan 10 mg can be effectively and safely used 
to treat migraine attacks in adolescents aged over 12 years.
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